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Preface
The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based
Practice Centers (EPCs), sponsors the development of evidence reports and technology
assessments to assist public- and private-sector organizations in their efforts to improve the
quality of health care in the United States. The reports and assessments provide organizations
with comprehensive, science-based information on common, costly medical conditions and new
health care technologies and strategies. The EPCs systematically review the relevant scientific
literature on topics assigned to them by AHRQ and conduct additional analyses when
appropriate prior to developing their reports and assessments.
This EPC evidence report is a Technical Brief. A Technical Brief is a rapid report, typically
on an emerging medical technology, strategy or intervention. It provides an overview of key
issues related to the intervention—for example, current indications, relevant patient populations
and subgroups of interest, outcomes measured, and contextual factors that may affect decisions
regarding the intervention. Although Technical Briefs generally focus on interventions for which
there are limited published data and too few completed protocol-driven studies to support
definitive conclusions, the decision to request a Technical Brief is not solely based on the
availability of clinical studies. The goals of the Technical Brief are to provide an early objective
description of the state of the science, a potential framework for assessing the applications and
implications of the intervention, a summary of ongoing research, and information on future
research needs. In particular, through the Technical Brief, AHRQ hopes to gain insight on the
appropriate conceptual framework and critical issues that will inform future research.
AHRQ expects that the EPC evidence reports and technology assessments will inform
individual health plans, providers, and purchasers as well as the health care system as a whole by
providing important information to help improve health care quality.
If you have comments on this Technical Brief, they may be sent by mail to the Task Order
Officer named below at: Agency for Healthcare Research and Quality, 5600 Fishers Lane,
Rockville, MD 20857 or by email to epc@ahrq.hhs.gov.
Andrew B. Bindman, M.D.
Director
Agency for Healthcare Research and Quality

Arlene S. Bierman, M.D., M.S.
Director
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director, EPC Program
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality

Christine Chang, M.D., M.P.H.
Laura Pincock, Pharm.D., M.P.H.
Task Order Officers
Center for Evidence and Practice Improvement
Agency for Healthcare Research and Quality
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manage, or mitigate any conflicts of interest.
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Medication-Assisted Treatment Models of Care for
Opioid Use Disorder in Primary Care Settings
Structured Abstract
Background. The majority of medication treatment for opioid use disorder (OUD) is provided in
primary care settings. Effective and innovative models of care for medication-assisted treatment
(MAT) in primary care settings (including rural or other underserved settings) could facilitate
implementation and enhance provision and uptake of agonist and antagonist pharmacotherapy in
conjunction with psychosocial services for more effective treatment of OUDs.
Purpose. The purpose of this Technical Brief is to describe promising and innovative MAT
models of care in primary care settings, describe barriers to MAT implementation, summarize
the evidence available on MAT models of care in primary care settings, identify gaps in the
evidence base, and guide future research.
Methods. We performed searches in electronic databases from 1995 to mid-June 2016, reviewed
reference lists, searched grey literature sources, and interviewed Key Informants. We
summarized representative MAT models of care in primary care settings and qualitatively
summarized the evidence on MAT models of care in primary care settings and identified areas of
future research needs.
Findings. We summarized 12 representative MAT models of care in primary care settings, using
a framework describing the pharmacological component, the psychosocial services component,
the integration/coordination component, and the educational/outreach component. Innovations in
MAT models of care include the use of designated nonphysician staff to perform the key
integration/coordination role; tiered care models with centralized intake and stabilization of
patients with ongoing management in community settings; screening and induction performed in
emergency department, inpatient, or prenatal settings with subsequent referral to community
settings; community-based stakeholder engagement to develop practice standards and improve
quality of care; and use of Internet-based learning networks. Most trials of MAT in primary care
settings focus on comparisons of one pharmacological therapy versus another, or on the
effectiveness of different intensities or types of psychosocial interventions, rather than on
effectiveness of different MAT models of care per se. Key barriers to implementation of MAT
models of care include stigma, lack of institutional support, lack of prescribing physicians, lack
of expertise, and inadequate reimbursement.
Conclusions. A number of MAT models of care have been developed and implemented in
primary care settings. Research is needed to clarify optimal MAT models of care and to
understand effective strategies for overcoming barriers to implementation. The models of
care presented in this technical brief may help inform the individualized implementation or
MAT models of care in different primary care settings.
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Background
Introduction
Opioid use disorder (OUD) has been identified by the Department of Health & Human
Services as a national crisis.1 OUD involves misuse of prescription opioids or use of illicit
heroin, and is defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5)2 as
“a problematic pattern of opioid use leading to clinically significant impairment or distress.” In
2014, approximately 1.9 million Americans 12 years or older were estimated to have OUD due
to prescription drugs and nearly 600,000 due to heroin use.3 OUD is associated with decreased
quality of life and increased morbidity and mortality. In 2013, an estimated 16,000 individuals
died as a result of prescription opioid overdose (a 2.5-fold increase from 2001) and
approximately 8,000 from heroin (a 4-fold increase from 2001).4 These trends have occurred in
conjunction with markedly increased rates of opioid prescribing for chronic pain;5-9 in fact, the
majority of heroin users now report that their first opioid of misuse was a prescription opioid, not
heroin.10 Challenges in the treatment of OUD include the relapsing nature of this condition, the
frequent presence of psychiatric and medical comorbidities, and the disproportionate impact on
those in socioeconomically disadvantaged settings with limited access to care.11,12 Lack of
control over purity leading to high variability in dose is an additional concern with heroin as
compared with prescription opioids.
As noted in 1997 by a National Institutes of Health consensus panel, OUD “is a medical
disorder that can be effectively treated with significant benefits for the patient and society.”13
According to the Substance Abuse and Mental Health Services Administration (SAMHSA),
medication-assisted treatment (MAT) is defined as the use of the U.S. Food and Drug
Administration (FDA)-approved opioid agonist medications (e.g., methadone, buprenorphine
products, including buprenorphine/naloxone combination formulations and buprenorphine monoproduct formulations [including a recently approved implantable formulation]) for the maintenance
treatment of OUD, and opioid antagonist medications (e.g., naltrexone products, including extendedrelease and oral formulations), in combination with behavioral therapies, to prevent relapse to opioid
use. MAT includes screening, assessment (which includes determination of severity of OUD,
including presence of physical dependence and appropriateness for MAT), and case management. It
has been suggested that the term MAT is misleading because it implies that medications play an
adjunctive role in treatment for OUD, and that it would be more accurate to simply refer to
multimodal therapy for OUD that includes use of medications as “treatment.”14,15 In this report, we
use the term MAT because it is widely used, well-understood (as defined by SAMHSA), and to help
distinguish medication-based from nonmedication based (e.g., detoxification/abstinence) approaches.
The term MAT is not meant to imply that medications play an ancillary role in treatment; rather,
medications are central to the concept of effective multimodal treatment for OUD. Medication is to
be provided in combination with comprehensive substance use disorder treatment, including but not
limited to: counseling, behavioral therapies, other clinically appropriate services in order for
individuals to achieve and maintain abstinence from all opioids and heroin, and, when needed,
pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically-driven,
person-centered, and individualized setting.”16 MAT has been shown to be more effective than
treatments that do not use medication in reducing the frequency and quantity of opioid use17,18
and may reduce the risk of overdose, improving social functioning and decreasing criminal
activity and infectious disease rates.19 The purpose of the medication component is to block the
euphoric and sedating effects of opioids, reduce the craving for opioids, and/or mitigate the
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symptoms of opioid withdrawal. Psychosocial interventions address the psychosocial
contributors to OUD and may help improve retention in care. Examples of psychosocial
interventions include cognitive-behavioral therapy, motivational enhancement therapy, and other
evidence-based psycho-social interventions in individual, group, or family counseling settings;
peer-delivered recovery support services; and assessment, coordination, and management of
other medical and psychiatric care needs such as provision of general primary care or treatment
for other substances use disorders, HIV or hepatitis C virus (HCV) coinfection, or pregnancy.20
In addition, comorbid psychiatric disorders are frequently present in patients with OUD and may
require treatment with psychiatric medications.

Current Practices
The White House and the Department of Health & Human Services recently identified
improved access to MAT as a key priority for reducing harms associated with OUD.1,21
Following the passage of the Harrison Narcotic Act in 1914 and prior to the Drug Abuse
Treatment Act (DATA) of 2000, MAT using opioid agonists could only be provided through
federally-approved opioid treatment programs and the partial opioid agonist buprenorphine was
not yet approved for the treatment of OUD.22 DATA 2000 enabled physicians to obtain a waiver
and prescribe for treatment of OUD schedule III-V medications approved by the FDA for this
purpose; currently the only such medication is buprenorphine (also available coformulated with
the opioid antagonist naloxone). An implantable formulation of buprenorphine was recently
approved by the FDA. Under federal law, physicians prescribing opioid agonists for OUD must
attest to the fact that they have access to ancillary counseling services. Although DATA 2000 has
increased access to buprenorphine in primary care settings, research indicates that access to and
use of buprenorphine remains limited.4,23 In many rural areas, for example, no buprenorphine
prescribers are available.24 Oral naltrexone, an opioid antagonist, has long been available for
treatment of OUD and extended-release naltrexone is recently available as a monthly
intramuscular injection. Naltrexone is not classified as a controlled substance and can be
prescribed in primary care settings by any physician, physician assistant, or nurse practitioner,
but its use has been limited. Extended-release naltrexone was approved by the FDA for treatment
of OUD in 2010; although oral naltrexone has long been available it is rarely used for this
indication. Although extended-release naltrexone does not require a waiver to prescribe for
OUD, its use currently appears low in comparison to buprenorphine, though reliable estimates on
utilization are not available. Methadone for treatment of OUD is a schedule II opioid that is
dispensed in licensed opioid-treatment programs (OTPs). Even in specialty substance use
disorder settings, medications approved for MAT appear to be underused, with one study
showing that MAT was used in only about one-third of patients.25 Therefore, understanding the
most effective and promising models of care and implementation strategies are critical for
optimizing the impact of initiatives to expand access to MAT.1

Objective of Technical Brief
The purpose of this Technical Brief is to conduct a scoping review describing the available
literature on MAT models of care and methods for effective MAT strategies, and to identify and
summarize key issues and gaps in the evidence base. A Technical Brief does not synthesize data
on outcomes or grade evidence. Rather, it seeks to summarize what evidence is available,
provide a conceptual or organizational framework to understand key components of the
intervention of interest, highlight promising new and innovative strategies, describe barriers to
2

implementation, and provide guidance regarding future research directions and priorities. The
focus of the Technical Brief is on implementation of MAT in primary care settings, including
rural or other underserved settings. Specifically, Guiding Question 1 provides an overview of
MAT models of care, Guiding Question 2 describes the context in which MAT is implemented,
Guiding Question 3 summarizes the current state of the evidence of MAT, and Guiding Question
4 addresses important issues and future directions for MAT. This technical brief is intended to
help determine the scope of future research, such as a subsequent systematic evidence review on
MAT.

Guiding Questions
1. Description/Overview of MAT for the Treatment of Opioid Use Disorder:
a. What are the different types or models of care of MAT that have been proposed or
used in clinical practice?
b. What are the potential advantages and disadvantages of these respective models of
care?
2. Context in Which MAT is Used:
a. In what settings is MAT currently implemented?
b. Are there special considerations for implementing MAT in primary care, including
rural or other underserved settings?
c. What are potential barriers to implementation, including resources needed, and how
do barriers vary according to the setting?
d. What kinds of training, certification, and staffing are required for various MAT
models of care?
3. Current Evidence on MAT:
a. What have published and unpublished studies reported on the use of and effectiveness
MAT in primary care settings, including rural or other underserved settings? The
technical brief will summarize the following information:
i. Patient population, including practice setting and country/location
ii. Details on MAT model of care, including the types of interventions used
(specifics of pharmacological and nonpharmacological treatments), provider
type/staffing needs, implementation strategy/mode of delivery, frequency, and other
factors
iii. Study design/size
iv. Comparator used in comparative studies
v. Concurrent/prior treatments
vi. Length of followup
vii. Outcomes measured
viii. Adverse events/harms/safety issues reported
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4. Important Issues and Future Directions for MAT:
a. What are promising new and innovative strategies in MAT models of care?
b. Given the current state of the evidence, what are the implications for the current level
of diffusion and/or further diffusion of MAT?
c. What are the ethical, equity, and/or cost considerations that impact diffusion,
decisionmaking, and/or conceptual thinking around MAT?
d. What are important areas of uncertainty for MAT?
e. What are possible key areas of future research on MAT, and what areas related to
MAT warrant a systematic review?
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Methods
The Technical Brief integrates discussions with Key Informants with searches of the
published literature and grey literature to inform the Guiding Questions.

Discussions with Key Informants
We identified and interviewed 11 Key Informants (8 nonfederal and 3 federal) to represent
broad and balanced perspectives relevant to MAT, with a focus on people with expertise or
experience related to implementation in primary care settings, including rural or other
underserved settings. The Key Informants represented the following stakeholder areas:
researchers, clinicians (including primary care providers and experts in management of
addiction), health policy, implementation, professional societies, patient groups, and federal
representatives. Potential Key Informants were asked to disclose conflicts of interest prior to
participation. The Agency for Healthcare Research and Quality (AHRQ) Task Order Officers
reviewed conflicts of interests; we extended invitations to potential Key Informants who did not
have conflicts of interest that precluded participation.
We organized and facilitated small group telephone discussions with the Key Informants (2
to 4 per call) to gain input on the Guiding Questions; group calls maximized efficiency and the
relatively small number of Key Informants on each call allowed all representatives the chance to
provide input. Members of our research team and the AHRQ Task Order Officers also attended
the calls. On the calls, we interviewed Key Informants using a semi-structured approach. Key
Informants were asked to respond to predetermined questions targeted to different Key Informant
perspectives, share more general insights, and interact with each other (Appendix A). The
questions were used as a guide, but we asked additional or supplemental questions based on
interviewee responses. We asked which MAT models of care are in use in primary care and other
related settings, including models of care which are not described in the published literature, and
asked Key Informants to describe the different components of the models and which components
were particularly effective or promising, the current challenges or barriers to implementation,
patient preferences, and future directions, including promising new and innovative models and
strategies for implementation. We also asked about specific issues to be aware of when
reviewing the literature, such as outcomes to be prioritized, meaningful length of followup, study
design issues, and how MAT models of care vary in terms of intensity, goals, and components of
care. Because we were particularly interested the feasibility and applicability of models of care
implemented in one setting or population compared with others and about identifying models of
care that may be particularly suitable for specific settings, including rural and other underserved
settings, we focused the questions and discussions in that area. The calls were recorded, and the
key points were summarized and shared with the group for clarification and additional input. We
reviewed all of the Key Informant input regarding successful and promising MAT models of care
and developed a framework for categorizing the different types of components in MAT models
of care, to help organize and provide a structure for future research and discussions in this area.
We then integrated feedback from the Key Informants with the expertise of our project team and
evidence identified from the published and unpublished literature.
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Grey Literature Search
To identify grey literature, the AHRQ Evidence-based Practice Center (EPC) Scientific
Resource Center sent email notification to relevant stakeholders about the opportunity to submit
Scientific Information Packets via the Effective Health Care Web site.
In addition, we conducted searches of the grey literature. Specifically, we searched
ClinicalTrials.gov and Health Services Research Projects in Progress (HSRProj) for ongoing
research, as well as Google Scholar, NIH Reporter, and Web sites of government agencies with
MAT initiatives. The grey literature searches were used to primarily inform Guiding Question 3,
but if information relevant to the other Guiding Questions was identified, it is also discussed in
the report.

Published Literature Search
We searched, reviewed, and summarized the available literature on MAT for OUD in
primary care settings to address Guiding Question 3. An experienced research librarian created
search strategies for the following databases: Ovid Medline, PsycINFO, the Cochrane Library,
SocINDEX, and CINAHL. The search strategies are available in Appendix B. Since OUD with
opioid agonists could not be treated in the primary care/nonaddiction treatment settings after the
passage of the Harrison Narcotic Act in 1914 until the year 2000, with the passage of the Drug
Addiction Treatment Act (DATA) 2000, and due to the focus of the report in primary care
settings and the large volume of abstracts, we restricted the start date for the searches to the year
1995 and later (to mid-June 2016). The search was also used to identify contextual evidence to
supplement the Key Informant input obtained for Guiding Questions 1, 2, and 4. We also
reviewed the reference lists of identified publications and solicited additional references from
Key Informants to supplement electronic searches. Searches will be updated while the report is
undergoing peer and public review in order to capture any recently-added publications. If any
new studies are identified from the update searches or arise as suggestions from the peer or
public review, they will be added to the report prior to finalization.
We applied predefined screening criteria to identify the most relevant and authoritative
evidence on MAT models of care in primary care settings. For Guiding Question 3, we focused
on the following sources of evidence: (1) high-quality Cochrane systematic reviews of MAT; (2)
randomized trials and cohort studies on the effectiveness of MAT models of care in primary care
settings; (3) randomized trials evaluating the effectiveness of newer pharmacological therapies
for MAT that could impact implementation or future models of care; and (4) randomized trials
on the effectiveness of more intensive versus less intensive psychological interventions with
MAT in primary care settings. To provide context for the other Guiding Questions, we also
identified published and unpublished studies describing MAT models of care in primary care
settings, including the setting for the model of care (e.g., urban vs. rural), patient characteristics
(e.g., age, presence of comorbid conditions, OUD related to prescription opioids for chronic pain
versus nonprescribed opioid use), and intervention characteristics (e.g., components of MAT
models of care, including degree of coordination and intensity of psychosocial interventions).
We also identified studies that provided contextual information on implementation strategies and
barriers in primary care settings, including rural and other underserved settings. We excluded
trials that focused on the dose or duration of pharmacological therapy, as the focus of this report
was on MAT models of care, not on details regarding how pharmacological therapy should be
provided.
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All titles and abstracts identified through searches were independently reviewed for
eligibility against our inclusion/exclusion criteria organized by PICOTS (population,
intervention, comparator, outcome, timing, study design) (Table 1) by a trained member of the
research team. Studies marked for possible inclusion by any reviewer underwent a full-text
review. For abstracts without adequate information to determine inclusion or exclusion, we
retrieved the full text and then made the determination. All results were tracked in an EndNote®
database (Thomson Reuters, New York, NY). Each full-text article was independently reviewed
by two trained members of the research team for inclusion or exclusion on the basis of the
eligibility criteria. If the reviewers disagreed, conflicts were resolved by discussion and
consensus or by consulting another member of the review team. Results of the full-text review
were also tracked in the EndNote® database, including the reason for exclusion for excluded fulltext publications when they did not meet the eligibility criteria.
For Guiding Question 3, we summarized information from systematic reviews and primary
studies that met inclusion criteria in summary tables. For systematic reviews, we summarized
information on year of publication, the purpose of the review, search dates and databases
searched, the number of studies included, populations and settings in the trials, MAT
intervention characteristics, the type of studies included, how quality was rated for included
studies, methods of synthesis, the total number of patients included, main findings (including
harms), and limitations (including whether the studies were primarily performed in an OTP or
addiction specialty settings, whether the studies were conducted outside the United States, and
other limitations). For randomized controlled trials, we summarized information on year of
publication, comparisons evaluated, duration of followup, sample size, population
characteristics, MAT model of care components, setting (including provider type and staffing if
that information was provided), outcomes evaluated, and main findings.
For Guiding Question 1, we summarized data sources for the various MAT models of care,
including published sources (with citations), unpublished sources (with URL information), and
Key Informant input.
Table 1. Inclusion and exclusion criteria for Guiding Question 3 on the efficacy and safety of MAT
for OUD
PICOTS
Populations

Include
Patients with OUD in primary care settings, including rural
or other underserved settings

Interventions

MAT (including the use of pharmacological therapy for OUD
with psychosocial interventions) for OUD16
1) MAT models of care in primary care settings vs. no MAT
2) MAT model of care vs. another MAT model of care
3) MAT model of care with more intensive psychosocial
interventions vs. less intensive psychosocial interventions
4) MAT model of care with newer pharmacological
component vs. placebo/no medication or vs. established
pharmacological component

Comparators
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Exclude
MAT in inpatient settings and
licensed treatment centers or
specialty addiction centers; MAT
provided outside the United States,
Canada, Europe, and Australia/New
Zealand
-Studies that focused on dose or
duration of pharmacological
component of MAT

PICOTS
Outcomes

Include
Exclude
Measures of retention in care or access
-Substance-use-related outcomes, including mortality,
overdose, substance use
Nonsubstance-use-related outcomes, including quality of
life, functional status, work status, engagement in criminal
activity, rates of unplanned pregnancy, acquisition or
transmission of infectious conditions, and others; in
pregnant women, maternal and fetal health outcomes
Timing
Any
-Study Design Cochrane systematic reviews
Nonsystematic reviews
Randomized controlled trials
Studies without original data
Cohort studies and case-control studies for comparisons #1 Non-English language
and #2
Nonhuman
MAT = medication-assisted treatment; OUD = opioid use disorder; PICOTS = population, intervention, comparator, outcome,
timing, study design
Note: Intervention uses the SAMHSA definition for MAT
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Findings
Overview
By definition, MAT involves the use of opioid agonists or antagonists in the treatment of
OUD. Two medications are currently used in the United States in office-based settings for
treating OUD: buprenorphine (with or without naloxone) and naltrexone (as daily oral or
extended-release formulations). Medications that have been used in primary care settings in other
countries but are not available for treatment of OUD in office-based settings in the United States
include methadone and sustained-release morphine; in the United States, methadone can
currently only be dispensed for treatment of OUD in licensed and accredited opioid treatment
programs or in rare research or demonstration settings.
We interviewed 11 Key Informants: 5 were clinicians with experience treating OUD or in
administration of office-based MAT (1 internal medicine/addiction, 1 family medicine/addiction,
1 addiction psychiatry, 1 psychology, 1 registered nurse); 4 had expertise in policy and
implementation (3 of these were from federal agencies, specifically the Health Resources and
Services Administration/HIV and AIDS Bureau [HRSA/HAB], the SAMHSA, and the National
Institute on Drug Abuse [NIDA]); 1 was from an organization representing opioid treatment
programs; and 1 represented the patient perspective who also directs a MAT clinic. The
interviews were conducted over four phone calls, with two to four Key Informants participating
in each call. Interviews lasted from 60 to 90 minutes and consisted of 8 to 12 questions. All
interviews took place in February and March 2016. A summary of data sources for Guiding
Question 1 describing various MAT models of care in primary care settings is shown in Table 2,
with sources in Table 3. For Guiding Question 3, abstracted data for randomized trials and
systematic reviews on MAT models of care in primary care settings are shown in Tables 4 and
5, respectively. We abstracted data from a total of 29 publications. A figure depicting the
literature flow is available in Appendix C, and a full list of included and excluded studies is
shown in Appendixes D and E, respectively.

Guiding Question 1: Medication-Assisted Treatment Models
of Care
A number of MAT models of care in primary care settings were described in the literature
and by Key Informants. A challenge in summarizing MAT models of care is that the models of
care frequently had overlapping characteristics, and varied in the degree to which they were
structured and adapted to specific settings. Key Informants consistently noted four important
components of MAT models of care: (1) pharmacological therapy (currently, buprenorphine
(with or without coformulated naloxone) or naltrexone (oral or extended-release); (2) provider
and community educational interventions; (3) coordination/integration of substance use disorder
treatment and other medical/psychological needs; and (4) psychosocial services/interventions.
However, they also noted variability in the degree to which each of these components is
addressed. We categorized four models as primarily practice-based and eight as systems-based,
though most have elements of both. We defined practice-based as a model that can be done in an
individual, standalone clinic; whereas systems-based models involve components across multiple
levels of the health care system to affect care throughout a network or local region.
Table 2 summarizes 12 representative models of MAT care, how they address these four key
components, and into which primary category they fall. These models were selected based on
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their influence on current clinical practice, innovation, or because they focus on delivery of MAT
in primary care in specific populations or settings (e.g., HIV or HCV-infected people, pregnant
women, or in rural settings). Table 3 summarizes sources used to describe the model. Ten of the
models were described in Key Informant interviews, six were described in the published
literature (including 4 models evaluated in randomized controlled trials), and eight models were
described in unpublished/grey literature sources.
In most (10 of the 12) models of care, buprenorphine/naloxone was the main (and frequently
the only) pharmacological therapy offered, with relatively little emphasis on provision of
naltrexone in most models. Key Informants noted that in many office-based settings there was
not a high demand for naltrexone (due in part to its mechanism of action as a pure opioid
antagonist) and the perception that it might not be the optimal therapy for most patients, in the
context of limited empiric data regarding its use in primary care. The degree to which
educational/outreach interventions were formally incorporated in MAT models of care varied.
For example, some models included little or no structured education or outreach, whereas in
other models there was an explicit educational/outreach component. Nonetheless, most Key
Informants noted that education is important for decreasing stigma associated with MAT among
both clinicians and patients, increasing the number of buprenorphine-waivered clinicians,
increasing buy-in from staff involved in treatment of OUD, and increasing understanding and
uptake of MAT by patients.
Educational/outreach efforts included local stakeholder meetings for training and to establish
and disseminate standards of care (Southern Oregon Model), mentored buprenorphine
prescribing and Internet-based provider education and support (Project Extension for Community
Healthcare Outcomes [ECHO]), training aimed at getting more physicians waivered for use of
buprenorphine, and education aimed at decreasing stigma and increasing use or uptake of MAT
by clinicians, office staff, and patients (various models). The SAMHSA-funded Physician
Clinical Support System-Buprenorphine (PCSS-Buprenorphine), a Web-based resource designed
to support physicians who prescribe buprenorphine by providing training and education and
linking them with a national network of trained physician mentors, was instrumental in
increasing the number of buprenorphine-waivered physicians during the initial expansion of
MAT into office-based settings.26 Now supplanted by the Prescribers’ Clinical Support SystemMedication Assisted Treatment (PCSS-MAT),27 PCSS represents a method for providing
physician education and support services that is widely available across geographic settings and
in different models of care.
Key Informants consistently noted that coordination/integration of care is critical for
successful delivery of MAT in primary care settings. Coordination/integration of care was an
explicit component of all of the more structured MAT models of care. In six MAT models (Hub
and Spoke, Office-based Treatment Model (OBOT), Massachusetts Nurse Care Manager Model,
Buprenorphine HIV Evaluation and Support (BHIVES) Collaborative Model, Project ECHO,
One Stop Shop), a specific nonphysician is designated with providing care integration and
coordination for treatment of OUD and coordinating primary medical care and mental health
needs. The care coordinator may also serve as the main point of contact for patients, allowing for
less extensive physician-patient contact. In these models, physicians primarily prescribe
buprenorphine/naloxone, have less frequent face-to-face visits with the patient, and provide
consultation as needed. This type of “glue” person was viewed as critical for offloading the
burden of care from physicians and allowing them to manage more patients with OUD
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successfully, with the provision that the glue person needs to have requisite skills and knowledge
in treating OUD.
Key Informants also consistently noted that availability of psychosocial services is essential
to successful MAT models of care, and that capacity to refer patients for appropriate counseling
is required to meet requirements for office-based MAT as specified in DATA 2000.28 The degree
to which psychosocial services are integrated into the MAT treatment setting, the intensity of
psychosocial treatments, and the intensity of psychosocial services, varied even within programs
implementing the same model of care. There is disagreement regarding the types or intensity of
psychosocial services required to implement successful office-based models of care in primary
care settings. Some Key Informants considered models of care without integrated,
comprehensive psychosocial services to be inadequate; other Key Informants noted that models
of care that included brief counseling with medication treatment have been shown to be effective
and that although such models might not represent the ideal, they may be easier to implement
and already represent a great improvement in terms of access to care and treatment outcomes.
Key Informants noted that the need for more intensive psychosocial services is likely to vary
according to the setting and population treated and that models of care that do not have more
intensive psychosocial services may find it difficult to manage more complex patients. In most
MAT models of care, additional psychosocial services, including management of psychiatric
comorbidities, group and individualized counseling, peer support, social and family support, and
community support services are available on-site or nearby. In the Collaborative Opioid
Prescribing (Co-OP) model, ongoing psychosocial services are provided by a partnering OTP.
Although the Key Informants noted a preference for comprehensive, on-site psychosocial
services, they noted that this was not always possible due to financial constraints or local
availability of services. The One Stop Shop model represents a unique model in which MAT is
provided in a preexisting mental health clinic with comprehensive psychosocial services and also
provides primary care and other health services. Several models of care focus on identification
and initiation of MAT in specific settings (e.g., emergency department, during hospitalization, or
in prenatal care), with referral to ongoing treatment in community-based/primary care settings.
The following section describes the 12 representative models of care in more detail,
including advantages and disadvantages of each.

Hub and Spoke Model
The system-based Hub and Spoke model was developed in Vermont.29-32 The model consists
of two levels of care, with the patient’s needs determining the appropriate level. In this model,
“hubs” are OTPs that serve as regional specialty treatment centers (currently numbering 6) that
provide traditional treatment for OUD and also have the capacity to either directly provide or to
organize comprehensive care and continuity of services in a home health model. “Spokes” are
clinics in the community that provide MAT and comprehensive care for less clinically complex
patients. Patients are screened to determine whether they are appropriate for initial stabilization
and management in a hub or spoke. The hubs provide care for clinically complex patients,
support tapering off MAT, dispense methadone if needed, and provide consultative services to
the spokes. Following stabilization, patients initially managed at a hub who do not require
ongoing management at the hub may have their management transferred to a spoke; conversely,
patients managed in a “spoke” who require a higher level of care may be transferred to a hub.
Buprenorphine/naloxone has been the primary pharmacological component in the spokes within
the Hub and Spoke model. The model is financed through a Medicaid health home model waiver
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state block grant. Its effect on outcomes has not been published. Vermont incentivized
implementation of buprenorphine/naloxone prescribing by funding online training for physicians
to obtain buprenorphine waivers and providing other technical assistance to physicians
prescribing buprenorphine. The Hub and Spoke model includes some educational outreach in the
community to increase the number of buprenorphine waivered physicians. Coordination and
integration occurs between the hub and spoke as well as within each spoke site, and is typically
carried out by a registered nurse, clinician case manager, or other “care connector” (e.g., via
peer-to-peer support or behavioral health workers). Psychosocial services are embedded within
spoke sites, including social workers, counseling, and community health teams.
An important advantage of the Hub and Spoke model is the availability of tiered care and the
availability of regional expertise in the management of OUD. The established relationships
between the hub and spokes promote ongoing coordination and integration, including efficient
consultation with the hubs and transfer of care to the hub as needed. Within the spoke sites in
this model of care, the use of designated nonphysician “care connectors” at the spoke sites and
availability of embedded psychosocial services are important advantages over models in which
the coordination/integration roles are less well defined or in which psychosocial services are not
available on-site. A potential disadvantage of the Hub and Spoke model is that a hub with the
appropriate expertise and resources may not be available in all settings that wish to implement a
MAT model of care. Also, the spokes in the Hub and Spoke model are likely to vary in the
degree of expertise and types of services provided.

Collaborative Opioid Prescribing Model
The system-based Collaborative Opioid Prescribing (Co-OP) model was developed in
Baltimore.33,34 Similar to the Hub and Spoke model, initial intake, induction with
buprenorphine/naloxone, and stabilization is performed at a center (in the Co-OP model, this is
an OTP). Patients are shifted to primary care clinics for ongoing MAT after stabilization on
medication. Unlike the Hub and Spoke model, in the Co-OP model psychosocial services are
generally provided concurrently on an ongoing basis by the OTP, rather than at the primary care
site. Some outreach and education is performed by counselors involved in Co-OP to community
physicians. Financing is through Medicaid and private insurance.
Like the Hub and Spoke model, an advantage of the Co-OP model is that initial evaluation
and management occurs in a specialty center; in addition, the specialty center continues to
provide psychosocial services following the handoff to the primary care site. Therefore, this
model takes advantage of the expertise and resources available at the OTP on an ongoing basis.
A potential disadvantage of the Co-OP model is that because ongoing psychosocial services are
provided by the OTP, it may require relatively close proximity between the primary care sites
and the OTP, which may not be available in all settings that wish to implement a MAT model of
care. Also, because the OTP in the Co-OP model provides ongoing services, this could limit the
number of patients that could be managed compared with the Hub and Spoke model, in which
ongoing care for most patients is more dispersed and provided more independently within the
spoke centers.

Office-Based Opioid Treatment
An early model for Office-Based Opioid Treatment (OBOT), a practice-based model, has
been widely disseminated throughout the United States. In OBOT, physicians who complete 8
hours of training and receive a DEA waiver number may prescribe buprenorphine/naloxone in
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the context of primary care While many providers offer OBOT without staff assistance, some
practices designate a clinic staff member, or “glue person” (often a nurse or social worker) who
works in collaboration with a primary care clinician to coordinate services.35-37 The glue person
is instrumental for coordinating and integrating care, including primary care and mental health.
Psychosocial services include regular brief counseling provided by the physician and glue person
or other staff; other psychosocial services vary but can include integrated cognitive behavioral
therapy or motivational enhancement therapy. Psychosocial services may be located on-site or
off-site. Early OBOT trials provided education and training of new buprenorphine prescribers,
which led to the development of the PCSS-Buprenorphine (now PCSS-MAT) model nationally,
including mentoring by more experienced prescribers. OBOT is financed through provider
reimbursement of billable visits. Medicare and many state Medicaid programs cover
buprenorphine, though prior authorization is frequently required.
A key advantage of the OBOT model is its use of a glue person to coordinate ongoing care.
This provides an efficient way for the prescribing physician to manage more patients. The model
also takes advantage of a training and mentoring resource available via the Web. Although
regular brief counseling is a core aspect of this model, a potential disadvantage is that the
availability of additional psychosocial services is highly variable, which could make
management more difficult for more complex patients. In addition, coordination and ongoing
relationships with OTPs appear relatively informal or undefined in this model.

Massachusetts Nurse Care Manager Model
This system-based model was developed in Massachusetts, where Medicaid reimburses
Federally Qualified Health Center nurses for OUD care management.38-40 This model is similar
to the OBOT model in that a key aspect is the use of a nonphysician to coordinate and manage
much of the care. Unlike the OBOT model, the Massachusetts model specifically uses nurse care
managers who team with primary care physicians to provide MAT (primarily
buprenorphine/naloxone, with integration of extended-release naltrexone over the last 2 years).
The nurse care manager performs initial screening, intake, and education, often with assistance
from a medical assistant. The nurse care manager also provides ongoing management of OUD
and other medical issues, including drop-in or same day visits, management of acute issues,
coordination of prior authorization requests, communication with pharmacists, and perioperative
care coordination. The diagnosis of OUD and appropriateness of MAT are confirmed by the
prescribing physician, who comanages the patient with the nurse care manager. One Key
Informant described an adaptation of this model at a community-based health care system in
Massachusetts in which a “care partner” (usually a master’s level individual who is not a nurse
care manager) performs this role. This model uses a training program to get more primary care
physicians involved in prescribing buprenorphine and education is provided on best MAT
practices; the nurse care manager receives training in MAT and addiction. Psychological services
are integrated on-site or nearby, though the specific services that are available vary from site to
site. Patients who require a higher level of care can be expedited into treatment in an OTP. The
model is financed through direct Medicaid reimbursement to FQHCs for nurse care manager
time as a billable service, in addition to usual Medicaid coverage for pharmacotherapy and
physician visits.
A key advantage of this model is that it uses a nonphysician to offload some of the burden
from prescribing physicians, which in turn enables the prescribing physicians to manage more
patients. This model also emphasizes training and education to engage more primary care
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physicians in prescribing buprenorphine. Another advantage of this model is that it may be more
sustainable financially, because Medicaid reimburses federally qualified health center (FQHC)
nurses in Massachusetts for OUD care management and the state supports additional
coordination services using Block Grant resources. However, this reimbursement mechanism is
not available in all states. A disadvantage is that the availability of psychosocial services and
whether they are present on-site vary. In addition, the model is highly dependent on the
availability of a skilled person who can assume the nurse care manager or analogous role
effectively.

Buprenorphine HIV Evaluation and Support Collaborative Model
The practice-based Buprenorphine HIV Evaluation and Support (BHIVES) Collaborative
model uses the OBOT framework to provide a chronic care model for providing buprenorphine
in HIV primary care settings.41-51 Like the OBOT Model, a clinic coordinator glue person
(typically a counselor or social worker) is essential for coordinating care, working in conjunction
with the primary care provider. HIV care can be provided by the primary care provider or by
another on-site provider in coordination with the primary care provider. BHIVES sites generally
have on-site psychological services, including individual counseling, though the types of services
vary. HIV clinics coordinate with affiliated OTPs for patients switching to or from methadone. A
HRSA52 monograph promotes adoption of BHIVES in United States HIV clinics and BHIVES is
considered the standard of care for engaging HIV-infected patients with OUD in treatment.53,54
Buprenorphine and HIV care are typically covered by patient insurance. Ryan White Care Act
funding supplements medication coverage, care coordination and counseling services in some
states.
An advantage of the BHIVES model is that it is specifically designed to address MAT, HIV
care, and primary care within a single setting. It also has the same advantages as other models
that use a glue person for chronic care management and coordination. A potential disadvantage is
that the availability of on-site psychological services and the types of available services vary and
are not well specified. In addition, it requires clinicians with expertise and knowledge in both
MAT as well as HIV care, which may not be available in all settings. PCSS now includes
physician mentors with expertise in HIV care, an educational model that could potentially be
expanded for other chronic comorbid conditions.

Project Extension for Community Healthcare Outcomes
Project Extension for Community Healthcare Outcomes (ECHO), a system-based model of
care first developed in New Mexico, links primary care clinics in rural areas with a university
health system utilizing an Internet-based audiovisual network for mentoring and education55-57
regarding an array of medical conditions. The University of New Mexico developed a module
for supporting rural primary care providers in MAT management. It emphasizes nurse
practitioner- or physician assistant-based screening with referral to a collaborating physician
prior to initiation of MAT and for ongoing treatment, typically with buprenorphine/naloxone.
Counseling and behavioral therapies are offered from all ECHO team members. Complex
patients can be referred for further assessment and/or evaluation at an OTP. There is also an
emphasis on recruitment of physicians for buprenorphine waiver training and provision of
continuing medical education in OUD. It is financed through various federal grants and
Medicaid.
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An important advantage of the ECHO model is that it enhances the ability of rural primary
care clinics to provide MAT though its Internet-based mentoring and educational network. The
ECHO model may be considered a rural adaptation of the Hub and Spoke or Co-OP models, in
that it engages the expertise of a “hub” center to assist in provision of MAT. A potential
disadvantage of the ECHO model over traditional tiered care models is that due to the
geographic distance between the primary care sites and the hub, initial intake and assessment
does not occur at the centralized hub, due to the dispersed and rural settings in which care is
provided. Rather, all care, including initial intake and assessment, occur at the primary care sites.
The limited availability of on-site or face-to-face expertise in MAT could pose challenges for the
management of complicated or high-risk patients. The ECHO model may have had some impact
in New Mexico placing among the top states in buprenorphine-waivered physicians per capita;
New Mexico has also had more rapid growth in the number of waivered physicians practicing in
rural areas than in other areas of the United States since its initiation in 2005.55 In addition, the
ECHO model focuses on utilizing mid-level care providers for performing initial screening,
which may be critical for expanding access to MAT in many rural settings. There is also a strong
emphasis on provision of psychosocial services in the ECHO model. The ECHO model is a teleeducation/tele-consulting approach considered distinct from telemedicine, as there is no direct
doctor-patient relationship between off-site experts and patients, who are de-identified. A
potential advantage of this approach is that it only requires basic, widely-available
teleconferencing technology and does not require the high startup costs required for Health
Insurance Portability and Accountability Act (HIPAA)-compliant telemedicine expansion or the
sustainable funding necessary to purchase and maintain telemedicine technology and services. A
potential disadvantage is the lack of direct contact between off-site experts and patients, which
could make it more difficult to manage complicated patients and obtain reimbursement for
providing consultative expertise.

Medicaid Health Home Model for Those With Opioid Use Disorder
The Medicaid Health Home Model is a flexible, system-based model through Centers for
Medicare and Medicaid Services that allows states that apply for a Medicaid waiver to integrate
MAT and behavioral health therapies with primary care for patients with OUD.58,59 Provider and
community education is emphasized to increase uptake (by clinicians and patients) and to
decrease stigma. A core aspect of this model is that core psychosocial services are required (i.e.,
comprehensive care management, care coordination, health promotion, comprehensive
transitional care/followup, individual and family support, and referral to community and social
support services). Some telehealth services are also offered, though their availability and use
vary. Implementation of Medicaid Health Home Models differs from state to state with
differences in how the models are structured and overlap with other models of care (e.g., Hub
and Spoke) described in this section. In several states (e.g., Rhode Island and Maryland),
implementation of the Medicaid Health Home Model has been in OTPs or psychiatric clinics,
rather than in primary care clinic settings,59 although as described above, the Hub and Spoke
model involves a tiered model of care that includes community-based “spokes.”
Buprenorphine/naloxone has been the primary pharmacological component of treatment, with
integration of injectable naltrexone over the last 2 years. States determine the structure of health
care delivery, for example with Hub and Spoke models in Vermont, and approach to payment,
which may include per member per month payments (Maryland) and weekly bundled payments
(Rhode Island) that fund care coordinators in addition to other billable health care services.

15

An advantage of the Medicaid Health Home Model is that it requires care coordination and a
set of core psychosocial services. In addition, provider and community education are emphasized
as key aspects of this model. The flexibility of this model is an advantage in enabling service
delivery and provision to vary according to the needs and resources of the particular setting. At
the same time, the flexibility of the model may be viewed as a disadvantage in that some aspects
(e.g., who provides coordination/integration, who performs initial screening and assessment) are
not standardized or well-defined.

Southern Oregon Model
The Southern Oregon Model is an example of a local and informal system-based model for
delivery of MAT in a rural primary care network.60 It focuses almost exclusively on
buprenorphine/naloxone. A notable characteristic of the Southern Oregon Model is that it has
used regular meetings of stakeholders (including regional Medicaid-accountable care
organizations) for education, training, and development of practice standards around the
prescription of opioids for chronic pain and addiction treatment. Coordination or integration of
care is variable and often limited, though an on-site clinical social worker is available. A leader
of this model is also medical director of a local federal oversight OTP clinic, providing a source
of referral and consultation to providers in the region. However, access to OTPs for complex
patients is not formally integrated. The model is financed through direct support from
Accountable Care Organizations and usual fee for service billing.
An advantage of this model is that it is a grass-root, community-based effort, which may
promote buy-in from clinicians and those in the community. This could serve as a model for
implementation of MAT in rural settings where there may be increased stigma associated with
MAT and resistance to its use. However, a number of key components of this model are not yet
well-defined, and a Key Informant noted that psychosocial services and coordination/integration
of care is often limited. The Key Informant also noted that the relationship with the local OTP is
suboptimal and at times office-based MAT is viewed as a competitor rather than a partner by the
OTP.

Emergency Department Initiation of Office-Based Opioid
Treatment
This system-based model focuses on the emergency department (ED) identification of OUD,
with buprenorphine/naloxone induction initiated in the ED.61 Patients are connected to ongoing
OBOT, then transferred to ongoing, office-based maintenance treatment or detoxification. Brief
“medical management” counseling is performed by physicians; other psychosocial services vary.
Medications, ED visits, and OBOT are funded through patient Medicaid and other insurance
plans.
An advantage of this model is that it identifies patients who might benefit from MAT and
may not have access to primary care, or only sporadic access. Initiation of
buprenorphine/naloxone in the ED also appears to increase retention in care rates versus a simple
referral. A potential disadvantage of this model is added congestion in the ED as a means to
access treatment. In the randomized trial that evaluated this model, ongoing management in
primary care settings was provided through the OBOT model, which may not be the model
available in all settings. However, the ED initiation model could be used to “feed” into various
office-based models of care, depending on what is available in the community.
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Inpatient Initiation of Medication-Assisted Treatment
This system-based model involves the identification of OUD in the hospital, with initiation of
MAT (methadone, buprenorphine/naloxone, or naltrexone) during the hospitalization by a
multidisciplinary addiction consult service.62 Patients are connected with primary care or
specialty addictions care (patients initiated on methadone must be followed in an OTP), where
treatment continues following hospital discharge. In some programs, when relevant, there is a
buprenorphine “bridge” clinic for stabilization prior to transitioning to primary care. Ongoing
psychosocial services are provided at primary care sites. A variation of this model involves
identification of OUD in the hospital and brief counseling, with facilitated referral to a
community-based clinic for induction of MAT and ongoing care following hospital discharge.63
Another variation uses a program nurse to identify inpatients with OUD, a bridge clinic for
initiation of methadone following discharge with provision of psychosocial services (case
management, group health education, counseling), and transition to another OTP for long-term
management; such a program could be adapted for office-based prescribing of
buprenorphine/naloxone.64 This model requires hospital support for initial development of
inpatient consult services.
Like the model involving ED initiation, an important advantage of inpatient screening and
initiation is that it identifies patients with complex morbidity and high risk of mortality who
otherwise may have had limited or no access to MAT. Likewise, inpatient initiation appears to
enhance retention in care rates versus simple referral for outpatient initiation of MAT after
hospitalization. Like the ED initiation model, this model of care focuses on the inpatient aspect,
but could be linked to one of the office-based models of care described above for ongoing
management. Patients initiated on methadone would not be eligible for referral to office-based
care.

Integrated Prenatal Care and Medication-Assisted Treatment
This practice-based model involves the provision of prenatal care to pregnant women who
are treated with buprenorphine in primary care. Women receive prenatal and postpartum care,
with care continued in an office-based setting after birth. Psychosocial services are provided onsite as well as through affiliated OTPs.
Like the models of ED and inpatient MAT initiation, this model can identify women with
limited or no access to care who come into contact with the medical system for prenatal care and
might benefit from MAT. In addition, women may be more amenable to MAT in the prenatal
setting due to concerns about the fetus and the desire to integrate care in one location. An
additional advantage of this model is that it provides ongoing care in the postpartum period,
providing additional continuity. Outcome studies conducted in OTP settings suggest that there is
a reduction in Neonatal Abstinence Syndrome when pregnant women with OUD are maintained
with buprenorphine rather than methadone.65,66 This model is typically financed through existing
Medicaid and other insurance reimbursement. A potential disadvantage is the need to transition
at some point to a setting that can provide ongoing, long-term care, unless the office-based
setting is equipped to do so. In one model (Southern Oregon), ongoing care is provided through
transition to a primary care clinic that can provide MAT.
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One Stop Shop Model
The One Stop Shop model was developed in response to an outbreak of HIV infection in
rural Indiana due to sharing of infected syringes.67 Based in an existing mental health clinic, it
provides integrated care including management of HIV/HCV infection, MAT, mental health, and
primary care needs, as well as other services including syringe exchange.68 This practice-based
model focuses on use of extended-release naltrexone as the pharmacological component. Peer
navigators and social workers provide coordination with primary care providers. Because it is
based in an existing mental health clinic, this model provides comprehensive on-site
psychological services, including a visiting psychiatrist who is available on a weekly basis for
consultation. Financing is from a combination of existing Medicaid and federal funding.
An advantage of this model is that it makes use of an existing mental health clinic to provide
comprehensive integrated care, including extensive psychosocial services under a single roof.
However, Key Informants noted that this model represents a unique response to the HIV
outbreak and may not be reproducible in other settings due to the resources and unique clinical
setting (i.e., an existing mental health clinic prepared to provide MAT) required. In addition, this
model was implemented recently, with more data needed to understand how successfully it can
be implemented.
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Table 2. Overview of MAT models of care for OUD in primary care (including rural or other underserved settings)
Model

Summary

Practice-based models
OBOT
Buprenorphine
prescribed by primary
care providers who
complete DATA2000
waiver training

Components
Pharmacologic

Education/Outreach

Coordination/Integration of
Care

Psychosocial

Other

Primarily
buprenorphine–
naloxone

Not a major component;
Provider Clinical Support
Service for MAT (PCSSMAT) available to mentor
primary care providers

A non-physician clinic staff
member sometimes used to
coordinate MAT prescribing
and integration with primary
and mental health care.

–

Treatment for OUD and
primary care, including HIV
care integrated in the same
setting. A non-physician clinic
staff coordinates care and
collaborates with HIV primary
care provider.
Treatment for OUD, mental
health, and primary care
(including HIV/HCV care)
provided in the same setting.
Peer navigators and social
workers provide coordination
with primary care providers.
Primary care clinic provides
MAT, as well as prenatal and
postpartum care; care
continued in office-based
setting for 1 y after delivery.
In some programs, women
can work with doulas.

Physician or other onsite
or off-site counseling at
least monthly; Other
psychosocial services
vary, including integrated
cognitive behavioral
therapy and motivational
enhancement therapy;
some psychosocial
services off-site.
On-site psychological
services vary, including
individual and group
counseling.

Centered in a mental
health clinic that provides
comprehensive
psychological services;
psychiatrist once weekly.

Syringe exchange and
other services also
available; Model
developed to respond to
specific outbreak of HIV
and Hepatitis C in rural
area.
–

Buprenorphine
HIV Evaluation
and Support
Collaborative
model

OBOT adaptation for
providing
buprenorphine–
naloxone in an HIV
primary care clinic
setting

Buprenorphine–
naloxone

Patient and provider
educational material
available online

One-stop shop
model

Integrated model
based in mental health
clinic to provide “onestop,” comprehensive
management of
HIV/HCV infection and
MAT
Model providing
prenatal care to
pregnant women who
are treated with
buprenorphine

Primarily
naltrexone

Provider education in
MAT, HIV, and hepatitis C
management

Buprenorphine

Not a major component,
though PCSS-MAT
service available.

Integrated
prenatal care
and MAT
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Services provided on-site
or via partnering OTP.

Coordination with OTP
for patients switching to
or from methadone

Model

Summary

System-based models
Hub-and-spoke
Centralized intake and
model
initial management
(Vermont)
(buprenorphine
induction) at “hub”;
patients are then
connected to “spokes”
in the community for
ongoing management

Components
Pharmacologic

Education/Outreach

Coordination/Integration of
Care

Psychosocial

Other

Primarily
buprenorphine–
naloxone

Outreach to prescribers in
the community to increase
the number of
buprenorphine-waivered
physicians

Coordination/integration
between hub and spoke as
well as within each primary
care site spoke. Registered
nurse clinician case manager
and/or care connector (peer
or behavioral health
specialist) for
coordination/integration of
care at spokes.
Required component, but
mechanism of coordination
varies.

Embedded in spoke sites,
including social workers,
counseling, and
community health teams.

Hubs provide
consultative services
and are available to
manage clinically
complex patients;
support tapering of
MAT; or prescribe
methadone, if needed

6 core psychosocial
services are required:
comprehensive care
management, care
coordination, health
promotion,
comprehensive
transitional care/follow-up,
individual and family
support, and referral to
community and social
support services.
Counseling and
behavioral therapies
offered from all ECHO
team members, including
CHWs; however, CHWs
and NPs provide
education/support;
psychosocial support,
including 12-step
programs; crisis
counseling; referrals; and
relapse-prevention plans.

Some telehealth
services offered

Medicaid health
home model

A flexible model that
provides MAT in
combination with
behavioral health
therapies and
integrated with primary
care

Primarily
buprenorphine–
naloxone

Provider and community
education emphasized to
increase uptake and
decrease stigma

Project ECHO
(New Mexico)

Model of care for
linking primary care
clinics in rural areas
with a university health
system, emphasizing
NP or PA screening
and MAT (physician
prescribing) combined
with counseling and
behavioral therapies

Primarily
buprenorphine–
naloxone

Mentored buprenorphine
prescribing for providers,
including an Internetbased, audiovisual
network for provider
education. Free
buprenorphine training
provided several times
yearly. ECHO staff
provide patient education
1-to-1 or in group setting.

20

NP/PA performs initial
evaluation and screening to
educate patient and refer to
collaborating physician for
treatment. NP/PA performs
monitoring treatment and
follow-up appointments,
including laboratory tests,
urine testing, monitoring,
patient education and
support, and other
coordination (e.g.,
vaccinations).

Refer any patients with
high or moderate risk
scores for opioid use to
NP for further
assessment and/or
referral to OTP

Model

Summary

Components
Pharmacologic

Education/Outreach

Collaborative
opioid
prescribing
model
(Maryland)

Links OTPs with officebased buprenorphine
providers; initial intake,
induction, and
stabilization performed
at OTP then shifted to
primary care clinic

Buprenorphine–
naloxone

Outreach performed by
counselors to community
physicians

Massachusetts
nurse care
manager model

A primary care–based
model that teams
nurse care managers
with primary care
physicians; nurse care
managers generally
perform initial
screening, intake,
education,
observed/supports
induction, follow-up,
maintenance,
stabilization, and
medical management
with the physician and
team
Model involving ED
identification of OUD;
buprenorphine–
naloxone induction
initiated in the ED;
coordination with
OBOT, nurse with
expertise in
buprenorphine working
in collaboration with
primary care clinician

Primarily
buprenorphine–
naloxone, with
recent addition of
extended-release
naltrexone

A training program exists
to get more physicians
(especially residents) and
faculty on board. The
Department of Public
Health trains staff on best
practices. Nurse care
managers receive 8 h of
training in MAT,
shadowing in model MAT
site, site visits, e-mail and
telephone support, case
review, quarterly training,
and an addiction listserv.

Buprenorphine–
naloxone

Not a major component

ED initiation of
OBOT
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Coordination/Integration of
Care
Initial assessment,
psychosocial treatment, and
expert consultation initiated in
drug treatment program and
patients transitioned to
primary care in a federally
qualified health center after
stabilization.
Nurse care managers
(registered nurses or family
NPs) manage 100 to 125
patients alongside primary
care clinicians, with
assistance from a medical
assistant. Alternatively, care
partners (usually persons
with a master’s degree)
assist the primary care staff
with screening, brief
intervention, and referral to
treatment.

Psychosocial

Other

Provided concurrently via
OTP, including ongoing
counseling and monitoring

In Baltimore, Maryland,
supports to facilitate
access to health
coverage through
Medicaid and to
coordinate care through
HealthCare Access
Maryland
Patients who require a
higher level of care can
be expedited into an
OTP, assistance with
transfers of care, and
day-support programs

OUD identified in ED and
patients started on
buprenorphine therapy and
connected to ongoing OBOT
provided by physicians and
nurses for 10 wk, then
transferred to office-based
ongoing maintenance
treatment or detoxification.

“Medical management”
counseling visits with
physician and nurse

Psychological services
are integrated on-site or
nearby

–

Model

Summary

Components
Pharmacologic

Education/Outreach
Not a major component

Inpatient
initiation of MAT

Model involving
identification of OUD in
the hospital and
connecting patients to
office-based MAT and
primary care

Buprenorphine–
naloxone and
naltrexone

Southern
Oregon model

A local and informal
model for delivery of
MAT in a rural primary
care network

Almost exclusively
buprenorphine–
naloxone

Coordination/Integration of
Care
MAT started by
multidisciplinary addiction
consult service during
medical hospitalization and
connected with primary care.
Treatment continued in
primary care; some programs
have buprenorphine “bridge”
clinic before transition to
primary care.
Relatively limited support for
coordination/integration of
care.

Psychosocial

Other

Provided at primary care
site

–

A group of local
On-site licensed clinical
Access to OTPs for
stakeholders from many
social worker with
complex patients not
perspectives who
experience in treating
formally integrated.
prescribes opioids
patients for pain and
(Oregon Pain Guidance)
addiction, not necessarily
meets regularly to develop
in MAT.
guidance and provide
education.
CHW = community health worker; ECHO = Extension for Community Healthcare Outcomes; ED = emergency department; HCV = hepatitis C virus; MAT = medication-assisted
treatment; NP = nurse practitioner; OBOT = office-based opioid treatment; OTP = opioid treatment program; OUD = opioid use disorder; PA = physician assistant
* Includes rural or other underserved settings
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Table 3. Sources for MAT models of care
Model

Published Literature

Grey Literature

Buprenorphine HIV (BHIVES) Integrated
Care Model

Altice, 201141
Chaudhry, 201169
Cheever, 201170
Egan, 201171
Fiellin, 201143
Finkelstein, 201172
Friedland, 201173
Korthuis, 201144
Korthuis, 201145
Lucas, 201046*
Lum, 201174
Schackman, 201175
Sullivan, 200648*
Sullivan, 201176
Vergara-Rodriguez,
201177
Weiss, 201150
Weiss, 201151
Stoller, 201534

https://www.careacttarget.org/library/beehive-buprenorphine-programtools49
http://www.slideshare.net/SarahCookRaymond/buprenorphine-therapyin-the-hiv-pruma47

Collaborative Opioid Prescribing (Co-OP)
Model
Emergency Department (ED) Initiation of
OBOT Model
Hub and Spoke Model (Vermont)

Inpatient Initiation of MAT
Integrated Prenatal Care and MAT
(Expert suggestion)
Massachusetts Nurse Case Manager
Model
Medicaid Health Home Model For Those
With Opioid Use Disorder

D’Onofrio, 201561*
--

Liebschutz, 201462*
-Alford , 200739
Alford , 201138
LaBelle, 201640
-

Key
Informant
Interview


http://www.atforum.com/pdf/CoOPtalkforONDCP_SAMHSAAug2015Sto
ller.pdf33
--



https://www.pcpcc.org/initiative/vermont-hub-and-spokes-healthhomes;30
http://www.healthvermont.gov/adap/documents/HUBSPOKEBriefingDo
cV122112.pdf31
http://www.leg.state.vt.us/reports/2014ExternalReports/299315.pdf29
http://www.achp.org/wp-content/uploads/Vermont-Health-Homes-forOpiate-Addiction-September-2013.pdf32
---



http://www.mass.gov/eohhs/gov/departments/dph/stop-addiction/gethelp-types-of-treatment.html78



https://www.medicaid.gov/Federal-Policy-Guidance/Downloads/CIB-0711-2014.pdf58
https://www.medicaid.gov/state-resource-center/medicaid-statetechnical-assistance/health-homes-technical-assistance/downloads/hhirc-health-homes-opiod-dependency.pdf59
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---

Model

Published Literature

Grey Literature

Office-based Opioid Treatment (OBOT)

Fiellin, 200237*
Fiellin, 200636*
Fiellin, 200835
-Komaromy, 201655

--

One Stop Shop Model
Project Extension for Community
Healthcare Outcomes (ECHO) (New
Mexico)
Southern Oregon Model

--

http://www.lifespringhealthsystems.org /68
http://echo.unm.edu/wp-content/uploads/2014/10/Opioid-Abuse-andAddiction-Management-Protocol.pdf56
http://www.aafp.org/news/chapter-of-the-month/20140930nmafpchapspot.html57
www.oregonpainguidance.org60

MAT = medication-assisted treatment
*Randomized controlled trial evaluating the model of care
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Key
Informant
Interview







Guiding Question 2: Settings in Which Medication-Assisted
Treatment Is Implemented
MAT is currently implemented in a variety of primary care settings. As described above,
models of care are implemented in general primary care settings as well as in settings in which
primary care is integrated with management of other conditions (e.g., HIV, pregnancy, mental
health). Certain models use the ED and inpatient settings to identify patients with OUD who
could benefit from induction and referral to office-based treatment. Most studies on MAT in
primary care settings have been conducted in centers that are either university-affiliated or
hospital-based. Because of the need to expand access to the medically underserved and to
support access to MAT in office-based settings for Medicaid beneficiaries58 and in FQHCs,79
aspects of MAT models of care developed in university-affiliated or hospital-based settings may
be transferable to community-based settings (e.g., use of a glue person for care coordination and
initial management, association with a centralized center of excellence, focus on integration and
coordination of care, and provision of psychosocial services).
DATA 2000 and the approval of buprenorphine in 2002 increased the availability of MAT by
permitting waivered physicians to prescribe buprenorphine for treatment of OUD. A 2006 report
from SAMHSA on the effects of the DATA Waiver Program found that about 56 percent of
waivered physicians were from a nonaddiction specialty80 (the proportion that were primary care
providers was not reported). However, not all waivered physicians actually prescribed
buprenorphine. Among waivered physicians, approximately two-thirds reported prescribing
buprenorphine. As of 2016, 21,781 physicians in the United States were certified to provide
buprenorphine treatment for up to 30 patients and 10,459 were certified to provide
buprenorphine treatment for up to 100 patients (total 32,240).81
There is geographic variability in the United States in access to and utilization of MAT. One
study found that buprenorphine use was highest in the Northeast (Vermont, Maine, and
Massachusetts) and lowest in South Dakota, Iowa, and Kansas.82 Many geographic areas in the
United States continue to experience shortages in access to MAT in primary care settings,
especially for patients living in rural areas. A survey found that only 3 percent of primary care
physicians in rural American had received a Drug Enforcement Administration (DEA) DATA
waiver to prescribe buprenorphine for OUD. Although the proportion of the United States
population residing in rural counties has declined substantially, about half of United States
counties have no buprenorphine-waivered physicians, and it is estimated that more than 30
million people live in counties (predominantly in nonmetropolitan areas) without access to
buprenorphine treatment.24,83,84 One study estimated that the number of physicians with
buprenorphine waivers (per 10,000 population) is about 7 to 9 times higher in urban compared
with rural settings.85 Another study found that states that opted to expand Medicaid following the
passage of the Affordable Care Act and establish a state-based health insurance exchange
experienced greater growth in the supply of buprenorphine-waivered physicians than states that
did not take these actions.86 In another study, states with increased Medicaid funding, more
opioid overdose deaths, and specific state guidance for office-based buprenorphine use were
associated with more buprenorphine-waivered physicians.84 We did not identify published
estimates regarding utilization of naltrexone for OUD. Key Informants indicated that oral
naltrexone is rarely used in primary care settings for OUD, given evidence suggesting
ineffectiveness and low compliance. Although Key Informants noted that extended-release
naltrexone is an appropriate treatment for OUD (approved for this indication by the FDA in
2010), they noted that utilization of extended-release naltrexone is highly variable.
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Facilitators and Barriers for Implementing Medication-Assisted
Treatment in Primary Care
Our Key Informants and literature review identified a number of important considerations for
implementing MAT in primary care. Insufficient institutional support is frequently cited as a
barrier to implementation.87,88 Institutional support may include sponsored training, resources
and staffing for coordination and integration of care, and provision of nonphysician staff with
expertise in OUD in order to implement a team-based approach, utilizing the skills appropriate to
each profession, as well as offloading some of the burden from prescribing physicians. Primary
care physicians also report important knowledge gaps in the area of addiction. These gaps reduce
the likelihood that they will prescribe MAT unless they have ready access to addiction expertise
(e.g., for complex patients). Addiction expertise could be accessed through telehealth initiatives
(e.g., Project ECHO), mentored prescribing (e.g., PCSS-MAT), coordination with local OTPs or
experts in addiction (e.g., Hub and Spoke model or Co-OP model), or other methods. Barriers to
telehealth include substantial start-up costs to be HIPAA-compliant, the need for ongoing
resources for staffing and maintenance, and variable reimbursement. Implementing MAT also
requires the integration of enhanced psychosocial services that may not be readily available in all
primary care settings. Because provision of MAT involves multiple practitioners with varying
types of expertise, improvement in communication and exchange of health information could
greatly facilitate implementation.
Another consideration is whether there are enough patients and sufficient reimbursement to
justify the resources and time required to implement MAT in primary care settings. Key
Informants noted that there needs to be a minimum number of waivered physicians available to
provide cross-coverage to avoid burn-out among prescribing physicians. In rural settings, Key
Informants observed that travel time can be a significant barrier, with some patients facing a 2hour commute to clinic; this can result in high travel costs and jeopardize the ability of patients
to maintain employment.89
Key Informants and the literature describe other barriers to implementation of MAT in
primary care settings.87,88,90 A key barrier is the relative lack of physicians with an FDA waiver
to prescribe buprenorphine for treatment of OUD. In December 2013, the average state had only
eight waivered physicians per 100,000 residents.91 Increasing the limit on the number of patients
that a physician can prescribe buprenorphine for OUD (currently 30 or 100) could be more
effective at increasing buprenorphine use and access than increasing the number of addiction
treatment facilities or increasing the number of waivered physicians.91 One study found that the
greatest impact on the amount of buprenorphine prescribed was the number of waivered
physicians able to treat up to 100 patients with buprenorphine.85 Although some Key Informants
felt that the current patient limits could be a barrier to implementation, most primary care
clinicians are not close to the prescribing limit and there are concerns that increasing the limits
could result in suboptimal care. Most (70% to 95%) physicians prescribing buprenorphine never
turned away any patient because of patient prescribing limits.92 As noted above, there seems to
be an unwillingness on the part of some physicians to prescribe, even though they have a
waiver.90 The same survey found that about two-thirds of physicians with a buprenorphine
waiver elected to not be included on the public Centers for Substance Abuse Treatment Locator
List in 2008; among these, about two-thirds reported no prescribing of buprenorphine in the last
90 days. Among physicians on the Locator List, 86 percent reported prescribing in the last 90
days. A related barrier is that DATA 2000 only permits “qualifying physicians” to prescribe
schedule III, IV, or V medications for treatment of OUD. The inability of physician assistants
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and nurse practitioners to prescribe buprenorphine is especially important in rural areas and low
income clinics, where these providers often outnumber physicians. One Key Informant noted that
in Oregon, such providers can prescribe any amount of schedule II opioid for pain, but cannot
prescribe buprenorphine for OUD. Pharmacists also play an important role in providing MAT
and could assist with dispensing, monitoring for adherence and diversion, and patient education.
Key Informants consistently noted that stigma towards MAT remains an important barrier to
implementation. Surveys of physicians90 describe stigma as pervasive and present among
physicians, clinic staff, patients, law enforcement, policymakers, insurers, and the community.
Key Informants noted that some patients do not even want to be in the same waiting room as
patients who are receiving MAT. This could result in significant barriers due to the need to
create separate clinic areas. In some states and other settings, abstinence is still viewed as a
“better” treatment than MAT, despite evidence to the contrary. The perception persists that using
an opioid agonist is replacing one addicting drug with another and promotes a preference for
detoxification and abstinence rather than agonist or antagonist therapy. In rural settings in
particular, Key Informants noted that MAT is often discouraged due to these beliefs. The Key
Informants noted a general lack of training and understanding90 regarding MAT even among
physicians, and emphasized the need for education of physicians as well as the community
regarding the evidence on effectiveness of MAT in order to increase the number of
buprenorphine waivered physicians, increase uptake of MAT by patients, and increase buy-in
among the community.
Other barriers to prescribing buprenorphine for OUD frequently cited in a survey of family
physicians in Vermont and New Hampshire includes inadequately trained staff, insufficient time,
inadequate office space, and cumbersome regulations.91 Several Key Informants noted that a fear
of potential Drug Enforcement Agency site visits,93 as per DATA 2000, was a deterrent to
obtaining a buprenorphine waiver.
Key Informants also noted barriers to use of extended-release naltrexone in primary care
settings. These include unfamiliarity with its use (this medication was approved by the FDA for
treatment of OUD in 2010), perception of low patient demand (due in part to its mechanism of
action as a pure opioid antagonist), the need to taper patients off opioids prior to starting
naltrexone, high cost, and potential for overdose in patients who relapse, since they are no longer
opioid-tolerant.
Reimbursement remains an important barrier.87 For example, although nurse care managers
in the Massachusetts model are reimbursed for their services, people serving similar functions in
other models are not necessarily reimbursed in the same way. Several Key Informants noted that
lack of reimbursement is a barrier to use of extended-release naltrexone. In the Project ECHO
model, off-site experts provide consultative expertise to primary care providers. There is no
doctor-patient relationship, and therefore these services are not reimbursable. Key Informants
also noted variability in policies related to reimbursement of provision of telemedicine services
in which there is an established, direct doctor-patient relationship. Without adequate
reimbursement, implementation of MAT models of care in many primary care settings is
unsustainable financially. Key Informants also noted onerous prior authorization requirements as
a barrier to prescribing buprenorphine, as well as arbitrary limits on the treatment duration and
doses. A survey of 45 states found that in 2013, only 11 percent of states had Medicaid policies
that excluded coverage for methadone and buprenorphine, whereas nearly three-quarters (71%)
had policies to cover both buprenorphine and methadone in Medicaid enrollees.94 However, there
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was also an increase in adoption of policies that could hinder access to buprenorphine or
methadone, such as prior authorization requirements.

Training, Certification, and Staffing Needs
DATA 2000 allows physicians to provide MAT using buprenorphine outside of licensed
OTPs if they complete 8 hours of training and submit an application to receive a waiver.
Physicians who obtain a waiver may be subject to periodic DEA audits of patient records (a
potential barrier to obtaining a waiver). DATA 2000 further specifies that brief counseling be
offered in conjunction with buprenorphine; this can be provided by the physician or
nonphysician staff. Models that integrate treatment of OUD with management of other chronic
conditions require expertise in management of those conditions; this can be provided by the same
physician that is managing the OUD or by other clinicians (not necessarily a physician).
Additional staffing and training requirements vary depending on the model of care. Several
models use a designated staff person to support the prescribing physician and serve as a main
point of clinical contact. In the Massachusetts model, an RN case manager performs screening,
supports the prescribing physician, and coordinates care and in Project ECHO, nurse
practitioners and physician assistants assume similar roles. There are no formal certifications or
trainings required to fulfill these roles, though DATA 2000 buprenorphine waiver trainings are
open to and attended by nonphysicians. The success of such models is likely to depend to a large
degree on the knowledge and skill that such people have in the area of addiction. Additional
staffing largely depends on the types of psychosocial services that are offered and may include
psychologists, social workers, peer counselors or mentors, psychiatrists, addiction specialists,
and others.

Guiding Question 3: Current Evidence on MedicationAssisted Treatment
Medication-Assisted Treatment Models of Care
We identified six trials on the effectiveness of MAT models of care in primary care/officebased settings36,37,46,48,61,62 (Table 4). Two trials compared buprenorphine/naloxone with more
intensive versus less intensive counseling in the OBOT (Yale) model.36,37 One trial compared
buprenorphine/naloxone with more intensive versus less intensive counseling among HIVinfected patients in the BHIVES model48 and another trial of HIV-infected patients compared
clinic-based buprenorphine/naloxone in the BHIVES model versus case management and referral
to an OTP.46 One trial compared the Emergency Department Initiation of OBOT model with
buprenorphine/naloxone versus referral for treatment (with or without a brief intervention)61 and
one trial compared the Inpatient Initiation of MAT model with buprenorphine/naloxone versus
linkage to care.62 No trial compared the effectiveness of one MAT primary care model versus
another.
Detailed tables of included trials for Guiding Question 3 are available in Appendix F.

Psychosocial Interventions
A number of trials have evaluated the comparative effectiveness of different psychosocial
interventions given as a component of MAT. However, relatively few trials on psychosocial
interventions have been conducted in office-based settings. A Cochrane review included 35 trials
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on the effectiveness of psychological therapies plus any agonist maintenance treatment as a
component of MAT for OUD (Table 5).95 Thirty-one trials were conducted in the United States.
In six trials the pharmacological component was buprenorphine/naloxone; the remainder
evaluated methadone (no study evaluated naltrexone). Of the trials, only one was conducted in a
primary care/community-based setting.36 It compared standard medical management with brief
(20 minutes/session) medically-focused counseling versus extended medical management with
more in-depth counseling (45 minutes/session) in patients prescribed buprenorphine/naloxone
and found no clear differences in effectiveness. We identified nine additional trials that evaluated
the effectiveness of more intensive psychosocial interventions or compared one psychosocial
intervention versus another in office-based settings (Table 4). The comparisons evaluated were
internet-based community reinforcement approach plus contingency management versus
contingency management alone,96 cognitive behavioral therapy versus standard counseling,97,98
network therapy versus standard medication management,99 cognitive behavioral therapy plus
directly observed, thrice-weekly buprenorphine versus physician management with weekly
buprenorphine, brief versus extended counseling,100-102 guided drug counseling plus standard
medical management versus medical management alone,37 and brief physician management
versus brief physician management plus nurse-administered drug counseling and adherence
management.48 The evaluation of different comparisons makes it difficult to assess overall
findings of the trials, but in most studies there were no clear differences in outcomes between
different psychosocial interventions.
Detailed tables of included systematic reviews for Guiding Question 3 are available in
Appendix G.

Pharmacological Therapies
A number of trials evaluated the pharmacological component of MAT. In all trials,
psychosocial interventions were also provided, though the psychological component was often
not well-described. Relatively few trials were conducted in office-based settings. Some trials
evaluated methadone and sustained-release morphine, which are not approved by the FDA for
this indication. We included those medications in this section as they could inform future MAT
strategies if they become available in the United States.
Buprenorphine
A Cochrane systematic review on buprenorphine as a component of MAT included 31 trials
(Table 5).17 The trials in the review focused on the effectiveness of buprenorphine (typically
formulated with naloxone) versus placebo or versus another medication, rather than the
effectiveness of MAT models of care per se. In addition, the studies had characteristics that
might impact applicability to MAT in United States primary care settings. Of the 31 trials, 15
were conducted in North America, and only two trials were clearly conducted in communitybased settings. One trial103 compared buprenorphine/naloxone versus buprenorphine versus
placebo in a United States setting and the other trial104 compared buprenorphine versus
methadone in an Australian setting (Table 4). We identified trials of a newer implantable
formulation of buprenorphine, but they were conducted in addiction settings and did not meet
inclusion criteria for this report.105,106
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Naltrexone
For oral naltrexone as a component of MAT, a Cochrane review included 13 RCTs (Table
5).107 Of these, four were conducted in the United States; all focused primarily on patients who
had been recently incarcerated, with none clearly conducted in primary care settings. For
extended-release naltrexone, another Cochrane review108 (Table 5) included only one trial on
effectiveness, which was conducted in an inpatient setting.109 Although searches for the
Cochrane review appear outdated (conducted in 2007), we identified no recent studies of
extended-release naltrexone conducted in primary care settings.109-115
Methadone
A Cochrane review of methadone as a component of MAT included 11 trials, but none were
clearly conducted in primary care or community-based settings (Table 5).18 We identified four
trials not included in the Cochrane review that compared methadone maintenance in an officebased setting versus a methadone clinic setting (Table 4). Two studies were conducted in
France116,117 and two studies in the United States.118,119 The trials generally found that methadone
maintenance in office-based settings was associated with similar outcomes as methadone
maintenance in addiction treatment settings.
Sustained-Release Morphine
A Cochrane review included three trials of sustained-release morphine as part of MAT (not
approved by the FDA for this use), but none of the trials were conducted in primary care/officebased settings.120

Special Populations
One Cochrane review evaluated the effectiveness of MAT in pregnant women, but evidence
on effectiveness of FDA-approved office-based treatments for MAT was extremely limited
(Table 5).121 In addition, although three trials (sample sizes 18, 30, and 175) evaluated
buprenorphine versus methadone maintenance treatment, none were conducted in primary care
or community-based settings. One trial evaluated buprenorphine/naloxone in community settings
for treatment of OUD in young people (15 to 21 years of age), but did not meet inclusion criteria
because it compared treatment for 12 weeks versus a 2-week taper.122 A Cochrane review
evaluated effectiveness of oral agonist treatment for OUD in injecting drug users on risk
behaviors and rates of HIV,123 but did not focus on medications approved for use in office-based
settings and only included two trials in which patients were managed in primary care settings
(Table 5).124,125 A trial of HIV-infected patients with OUD found no difference between officebased treatment with buprenorphine/naloxone versus referral to an OTP in HIV RNA levels and
CD4 counts.46 Trials of MAT in office-based settings primarily enrolled patients with OUD due
to heroin; we identified no systematic review or randomized trial on effectiveness of MAT in
primary care settings, specifically patients with OUD related to prescription opioids. Another
Cochrane review of MAT for OUD related to prescribed opioids included six trials that found
that methadone or buprenorphine appeared equally effective for outcomes related to opioid use
and treatment retention (Table 5).126 Five of the trials were conducted in the United States, but
none of the studies were conducted in primary care settings.
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Table 4. Trials for Guiding Question 3
Model name
Author, year

Comparators

Followup

N

Country

Population
Characteristics

Findings

MAT Models of
Care
30 days
D'Onofrio, 201561 Screening and referral to treatment (referral) vs.
screening, brief intervention, and facilitated
referral to community-based treatment services
(brief intervention) vs. screening, brief
intervention, ED-initiated treatment with
buprenorphine/naloxone, and referral to primary
care for 10-week followup (buprenorphine)
Buprenorphine/naloxone and medication
13 weeks
Fiellin, 200237
management (thrice-weekly sessions with a nurse
and a monthly meeting with a physician) vs.
buprenorphine and medication management plus
drug counseling (not described)

Fiellin, 200636

Liebschutz,
201462

Lucas, 201046

329

USA

14

USA

Standard medical management (20 minutes with
a nurse) and once-weekly medication dispensing
(buprenorphine/naloxone) vs. standard medical
management and thrice-weekly medication
dispensing vs. enhanced (45 minutes with a
nurse) medical management and thrice-weekly
medication dispensing
All groups met monthly with a physician
Detoxification plus referral vs. induction plus
contact from long-term opioid agonist treatment
staff that facilitated linkage to hospital-associated
primary care buprenorphine/naloxone treatment

24 weeks

166

USA

6 months

139

USA

Clinic-based, nurse-administered treatment with
buprenorphine/naloxone vs. case management
and referral to an intensive opioid treatment
program (referred treatment)

12 months

93

USA

76.3% male
mean age 31 years
34.3% use alcohol
to intoxication

Among opioid-dependent patients, ED-initiated buprenorphine treatment vs
brief intervention and referral significantly increased engagement in
addiction treatment, reduced self-reported illicit opioid use, and decreased
use of inpatient addiction treatment services but did not significantly
decrease the rates of urine samples that tested positive for opioids or of HIV
risk. These findings require replication in other centers before widespread
adoption.
71% male
Overall, patients had fewer positive urine opioid tests and experience high
mean age 36 years treatment retention through the maintenance phase; fewer patients in
medication management group vs. medication management plus counseling
79% with
group achieved greater than or equal to 1 week of negative urine opioid
history/current
tests, although this difference was not statistically significant; A greater
alcohol
proportion of the medication management plus counseling group had
dependence
negative urine opioid tests compared with the medication management
alone group, although this difference was not statistically significant.
78% male
The efficacy of brief weekly counseling and once-weekly medication
mean age 36 years dispensing did not differ significantly from that of extended weekly
counseling and thrice-weekly dispensing.

71.2% male
Compared with an inpatient detoxification protocol, initiation of and linkage
mean age 41 years to buprenorphine treatment is an effective means for engaging medically
hospitalized patients who are not seeking addiction treatment and reduces
illicit opioid use 6 months after hospitalization. However, maintaining
engagement in treatment remains a challenge.
72% male
Participation in opioid agonist therapy was significantly higher in clinic-based
median age 45-46 buprenorphine than for referred treatment. Positive test results for opioids
years
and cocaine were significantly less frequent in clinic-based buprenorphine
73% positive for
than in referred treatment, and study participants receiving clinic-based
hepatitis C
buprenorphine attended significantly more HIV primary care visits than those
antibody
receiving referred treatment. Use of antiretroviral therapy and changes in
10% AIDS-defining HIV RNA levels and CD4 cell counts did not differ between the 2 groups.
opportunistic
condition in
previous 3 month
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Model name
Author, year
Sullivan, 200648

Comparators

Followup

N

Country

12 weeks

16

USA

Buprenorphine/naloxone and individual
12 weeks
counseling plus contingency management (based
on urine results linked to points for gift cards or
money) vs. buprenorphine and individual
counseling and contingency management plus
internet-based community reinforcement
approach
Both groups had individual counseling every 2
weeks
Buprenorphine/naloxone and medication
13 weeks
management (thrice-weekly sessions with a nurse
and a monthly meeting with a physician) vs.
buprenorphine and medication management plus
drug counseling (not described)

170

USA

54% male
13% with
concurrent alcohol
dependence

14

USA

71% male
mean age 36 years
79% with
history/current
alcohol
dependence

Standard medical management (20 minutes with
24 weeks
a nurse) and once-weekly medication dispensing
(buprenorphine/naloxone) vs. standard medical
management and thrice-weekly medication
dispensing vs. enhanced (45 minutes with a
nurse) medical management and thrice-weekly
medication dispensing
All groups met monthly with a physician
Physician management (15-20 minutes weekly for 24 weeks
the first 2 weeks, every 2 weeks for the next 4
weeks, and then monthly) with
buprenorphine/naloxone or physician
management with buprenorphine/naloxone plus
CBT (up to 12 50-minute weekly sessions during
the first 12 weeks of treatment)
Buprenorphine/naloxone plus medication
18 weeks
management (2 individual sessions per week) vs.
buprenorphine plus network therapy (1 individual
and 1 group counseling session per week)

166

USA

141

USA

74% male
The effectiveness of physician management did not differ significantly from
mean age 34 years that of physician management plus cognitive behavioral therapy.

66

USA

76% male
Network therapy led to significantly more negative urine toxicologies and
mean age 36 years more network therapy than medication management patients had positive
outcome relative to secondary heroin use by the end of treatment

Buprenorphine/naloxone and physician
management (brief, biweekly) vs.
buprenorphine/naloxone and physician
management plus once-weekly drug counseling
and adherence management

Population
Characteristics
94% male
mean age 47 years
29% reported one
or more days of
alcohol use in past
30 days
100% HIV positive
81% HCV positive

Findings
There was no difference in treatment retention or illicit drug use by
counseling group; Overall, the proportion of opioid-positive weekly urine
screens decreased substantially over trial; CD4 counts remained stable; viral
load declined significantly; demonstrated feasibility of integrating
buprenorphine into HIV clinical care for treatment of opioid dependence

Psychosocial
Interventions
Christensen,
201496

Fiellin, 200237
(also a model of
care)

Fiellin, 200636
(also a model of
care)

Fiellin, 201397

Galanter, 200499

Compared with those receiving contingency management-alone, community
reinforcement approach recipients had more total days of abstinence and
were less likely to drop out of treatment; prior treatment for opioid
dependence moderated the additional improvement of community
reinforcement approach for longest continuous days of abstinence

Overall, patients reduced opioid-positive urine toxicology tests and good
retention through maintenance; less patients in medication management
group vs. medication management plus counseling group achieved greater
than or equal to one week of opioid-free urine screens, though this
difference was not statistically significant; A greater proportion of the
medication management plus counseling group had opioid-free urine
screens compared with the medication management alone group, though
this difference was not statistically significant
78% male
The efficacy of brief weekly counseling and once-weekly medication
mean age 36 years dispensing did not differ significantly from that of extended weekly
counseling and thrice-weekly dispensing
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Model name
Author, year

Comparators

Followup

N

Country

Moore, 201298

Buprenorphine and physician management (15
minute sessions weekly) vs. buprenorphine and
physician management plus CBT (45 minute
sessions weekly, depending on therapist
availability)

12 weeks

55

France

Sullivan, 200648
(also a model of
care)

Buprenorphine/naloxone and physician
management (brief, biweekly) vs.
buprenorphine/naloxone and physician
management plus once-weekly drug counseling
and adherence management

12 weeks

16

USA

Tetrault, 2012100

Physician management (brief, once every 2
12 weeks
weeks) vs. physician management plus enhanced
medical management (45 minutes weekly;
focused on drug counseling and adherence to
anti-retroviral treatment); used
buprenorphine/naloxone

47

USA

Weiss, 2011101
Prescription
Opioid Addiction
Treatment Study
(POATS)

Phase 1: Standard medication management (after
initial session,15-20 minute s weekly, then
biweekly sessions with a physician) with
buprenorphine/ naloxone vs. standard medication
management with buprenorphine/ naloxone plus
opioid dependence counseling (45-60 minute
sessions with a counselor, twice weekly then
biweekly)
Phase 2 (extended treatment for those who
relapsed): Standard medication management (2
visits first week, then weekly) with buprenorphine/
naloxone vs. standard medication management
with buprenorphine/ naloxone plus opioid
dependence counseling (twice weekly then
biweekly)
See above

Phase 1:
12 weeks
Phase 2:
24 weeks

653

USA

9 month
treatment;
42 month
followup

375

USA

Weiss, 2015102
Prescription
Opioid Addiction
Treatment Study
(POATS)

Population
Findings
Characteristics
74% male
Analyses adjusting for baseline characteristics showed no significant
mean age 39 years differences between groups on retention or drug use based on self-report or
urines. Patient satisfaction was high across conditions, indicating
acceptability of CBT counseling with observed medication. The number of
CBT sessions attended was significantly associated with improved outcome,
and session attendance was associated with a greater abstinence the
following week.
94% male
There was no difference in treatment retention or illicit drug use by
mean age 47 years counseling group; Overall, the proportion of opioid-positive weekly urine
29% reported one screens decreased substantially over trial; CD4 counts remained stable; viral
or more days of
load declined significantly; demonstrated feasibility of integrating
alcohol use in past buprenorphine into HIV clinical care for treatment of opioid dependence
30 days
100% HIV positive
81% HCV positive
39% male
At end of trial, no difference between groups in percentage of opioid
mean age 47 years negative urines, maximum duration of continuous abstinence, or retention;
the percentage of subjects with detectable viral loads decreased from
mean 4 days of
alcohol use in past baseline across both groups similarly; overall, providing extended
counseling in this setting is feasible but does not provide detectable
30 days
improvement in outcomes
mean 12 years
duration of HIV
diagnosis
26% HCV positive
60% male
During phase 1, only 6.6% of patients had successful outcomes, with no
mean age 33 years difference between standard medical management or standard medical
management plus opioid dependence counseling. During phase 2, 49%
27% alcohol
dependence during attained successful outcomes, with no difference between groups. Success
rates 8 weeks after completing the buprenorphine-naloxone taper (phase 2,
lifetime
week 24) dropped to 8.6%, again with no difference between groups.

56% male
mean age 33 years
old
3.7% with alcohol
dependence in
past year
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Few participants had successful opioid outcomes in phase 1; almost half
had successful opioid treatment in phase 2; addition of opioid dependence
counseling to medication did not improve outcomes; one third of those in
followup abstained and were not on agonist medication, one third were
abstinent on agonist therapy and another third were using opioids (followup
outcomes not described by group)

Model name
Author, year

Comparators

Followup

N

Country

12 months

221

France

Fiellin, 2001118

Primary care-based methadone (weekly physician 6 months
sessions and monthly counseling session) vs.
narcotic treatment program-based methadone (1
to 3 sessions per week dose, weekly group
counseling, and monthly individual counseling)

46

USA

Fudala, 2003103

Daily buprenorphine/naloxone vs. buprenorphine 4 weeks for 323 for USA
vs. placebo
efficacy; 52 efficacy;
All participants received HIV counseling and up to weeks for 472 for
safety
safety
1 hour of individualized counseling per week;
emergency counseling and referrals provided

King, 2006119

Routine care (methadone dispensing window for
weekly doses and monthly counseling for 20
minutes) vs. methadone maintenance clinic
(monthly observed dose, take home supply,
monthly 20 minute counseling session with
medical provider) vs. primary care basedmethadone (monthly observed dose, take home
supply, monthly 20 minute counseling session
with office physician)
Methadone vs. buprenorphine administered
under naturalistic conditions by 18 communitybased and 1 specialist-based sites by general
practitioners and community pharmacists
(Buprenorphine Implementation Trial)

Population
Characteristics

Findings

Pharmacological
Therapies
Carrieri, 2014116
See also Roux,
2012117

Lintzeris, 2004104

Induction of methadone in primary care vs.
specialty care

84% male
median age 32
years
33% had
hazardous alcohol
consumption
2% HIV-positive
19% HCV-positive
65% male
mean age 42 years
17% HIV-positive

Under appropriate conditions, methadone induction in primary care is
feasible and acceptable to both physicians and patients. It is as effective as
induction in specialized care in reducing street-opioid use and ensuring
engagement and retention in treatment for opioid dependence.

There was no significant between-group difference on illicit drug use or
patients with clinical instability; Significantly more office-based patients
thought that quality of care was excellent; There were no group differences
in functional status or use of health, legal, or social services; Overall, results
supported feasibility and efficacy of transferring stable opioid-dependent
patients to primary care for methadone maintenance
65% male
Efficacy study terminated early due to greater efficacy of
mean age 38 years buprenorphine/naloxone and buprenorphine vs. placebo; Proportion of
opiate-negative urine samples significantly less among both MAT groups vs.
placebo; MAT groups reported significantly less opiate craving than placebo;
Rates of adverse events similar in active-treatment and placebo groups;
findings from open-label followup indicated combined treatment was safe
and well tolerated
62% male
Generally low rates of drug use or failed medication recall with good study
mean age 44 years retention; No between-group differences on ASI scores; Treatment
satisfaction was high in all groups and patients in all groups rated strong
quality of therapeutic alliance; methadone medical maintenance patients in
both office and clinic-based care initiated more new employment or
social/family activities than routine care; most methadone medical
maintenance patients reported a preference for office-based care compared
with clinic-based

12 months

92

USA

12 months

139

Australia 58% male
Among methadone stabilized patients, mean retention time was similar
mean age 30 years between groups; among heroin users, there was a trend towards improved
retention among those taking methadone compared with those on
buprenorphine, though this was not statistically significant; There were
significant reductions in heroin use in all groups over time and a trend
toward lower heroin use among heroin users on buprenorphine

ASI = Addiction Severity Index; CBT = cognitive behavioral therapy; ED = emergency department, MAT = medication-assisted treatment
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Table 5. Cochrane Systematic Reviews for Guiding Question 3
Author, Year

Amato, 201195

Ferri, 2013120

Gowing,
2011123

Lobmaier,
2008108

Intervention
Characteristics

Population
and Setting

Countries

Types of
Studies
Included
RCTs, CCTs

No. of Included
Findings
Studies
No. of Patients
Any psychosocial
OUD due to
USA,
35 studies
Comparing any psychosocial intervention plus
intervention plus any opiates (not
Germany,
4319 patients maintenance pharmacological treatment to standard
agonist vs. any
specified);
Malaysia,
maintenance treatment, shows no significant
agonist alone;
setting not
China,
advantage of adding psychosocial interventions for
methadone,
described
Scotland
retention in treatment and at followup, abstinence
buprenorphine,
(appears
from opiates during treatment or at followup,
LAAM; models of
mostly
compliance, psychiatric symptoms, and depression.
care not described
specialist
Also, there was no significant difference in
centers)
outcomes comparing psychosocial approaches. Of
note, standard pharmacological treatment generally
offers counseling services.
Slow-release oral
OUD due to
Australia
RCTs, quasi3 studies
Limited evidence that sustained-release oral
morphine vs. other
heroin; Setting and Austria randomized
195 patients morphine is at least similar to other MAT
MAT medications;
not described
medications for retention and other clinical
(one study only
models of care not
outcomes
provided
described
conference
abstract)
Buprenorphine,
OUD due to
USA, UK,
RCTs,
38 studies
Oral substitution treatment with methadone or
methadone, or LAAM heroin; majority Australia,
observational
12400 patients buprenorphine is associated with significant
for substitution
prospective
reductions in illicit opioid use, injecting use, and
injecting drug Italy,
therapy (alone or vs. users or with
Germany,
studies, crosssharing of injecting equipment; also led to fewer
others); models of
sectional
drug users reporting multiple sex partners or
recent history Canada,
care not described
studies
(last 3 months); Malaysia,
exchanges of sex for money or drugs but no change
users of other Ukraine with
in condom use; reduced drug risk behaviors led to
one study in
injectable
reduced HIV; one study partially done in primary
multiple
drugs also
care showed significant reductions in proportion
countries
included;
injecting, sharing injecting equipment, and having
mostly
unprotected sex in those on methadone treatment.
specialist
treatment
centers
Three depot and two OUD not
Australia,
RCTs for
1 study for
One study found high-dose naltrexone depot
implant formulations specified;
Germany,
effectiveness;
effectiveness injections significantly increased days in treatment
of naltrexone (10 of effectiveness USA,
prospective
60 patients for vs. placebo and vs. low-dose with no group
17 depot studies
study in
Norway,
controlled and
effectiveness differences on patients retained in treatment;
used sustained
outpatient
Spain, UK
uncontrolled
release form) vs.
setting
trials, caseplacebo, different
series, and
naltrexone doses,
record-linkage
oral naltrexone, or
for safety
methadone; in
evaluation
addition to
medication, all
patients offered
relapse prevention
therapy
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Limitations

Focused on effectiveness of
psychotherapy interventions in addition to
standard interventions; setting not
described (appears mostly specialist
centers); 31 studies in USA

Focused on effectiveness of medications;
trials with no description of setting; no
studies in USA

Focused on effectiveness of medications
on HIV and behaviors; 2 studies included
primary care settings; 26 studies in USA

Focused on effectiveness and adverse
events of medications; effectiveness
study in outpatient setting (no further
details); effectiveness study and most
safety studies done in USA

Author, Year

Intervention
Characteristics

Mattick, 200918 Methadone
maintenance vs.
placebo or other
nonpharmacological
therapy (wait-list
control, drug-free
rehabilitation,
detoxification);
models of care not
described (some
studies included
counseling in the
intervention but this
was not described)
17 Buprenorphine
Mattick, 2014
maintenance vs.
placebo or
methadone; models
of care not described

Minozzi,
2009127

Any maintenance
treatment alone or in
combination with
psychological
intervention vs. no
intervention, other
pharmacological or
psychosocial
intervention;
models of care not
described

Population
and Setting

Countries

Types of
Studies
Included
RCTs

OUD due to
opioids (not
specified);
most studies
done in
specialist
medical or
research
facilities (3 in
prison setting)

USA,
Australia,
Hong Kong,
Thailand,
Sweden

OUD due to
heroin or other
opioids;
settings not
described

North
RCTs
America,
Europe,
Asia, Middle
East,
Australia

31 studies
5430 patients

OUD due to
heroin;
adolescents;
outpatient

USA

2 studies
187 patients

RCTs and
controlled
clinical trials

No. of Included
Findings
Studies
No. of Patients
11 studies
Methadone was significantly more effective than
1969 patients nonpharmacological approaches in treatment
retention and suppression of heroin use but not
different in criminal activity or mortality
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Buprenorphine was superior to placebo in
participant retention at all doses; only high-dose
buprenorphine (not low- or moderate-dose) was
more effective than placebo in suppressing illicit
opioid use; flexible dosed buprenorphine was less
effective than methadone in participant retention
with no group differences in suppression of opioid
use; low-dose methadone was more likely to retain
participants and limit opioid use than low-dose
buprenorphine but high and medium-dose
methadone were not more effective than high and
medium-dose buprenorphine for participant
retention and illicit opioid use
Limited evidence that maintenance treatment was
superior in patient retention but not in reducing illicit
opioid use; Opioid use at 1 year followup was
significantly lower in the maintenance group and
more patients in this group were enrolled in other
addiction treatment at followup

Limitations

Focused on effectiveness of medication;
no studies appear to be have been done
in primary care; 6 studies in USA

Focused on effectiveness of medications;
setting not described; 15 studies from
North America

Focused on effectiveness of medications;
outpatient setting (unclear if primary
care); all trials done in USA

Author, Year

Minozzi,
2011107

Minozzi,
2013121

Nielsen,
2016126

Intervention
Characteristics

Types of
Studies
Included
Oral naltrexone alone OUD due to
USA, Israel, RCTs
or in combination with heroin alone or Russia, Italy,
multiple drugs; Spain,
psychosocial
outpatient only China,
treatments vs.
placebo, no
Malaysia,
intervention, other
Germany
pharmacological
treatments, or
psychosocial
treatments; models of
care not described
Methadone vs.
buprenorphine or
slow-release
morphine; models of
care not described

Population
and Setting

Opiate
addicted
pregnant
women (OUD
not specified);
inpatient and
outpatient
settings
Methadone vs.
OUD due to
buprenorphine; also, pharmaceutical
buprenorphine
opioids; 5
maintenance vs.
studies
either buprenorphine conducted in
taper (in addition to
outpatient
psychological
settings, 1
treatment) or brief
study hospitalintervention and
based
referral to treatment treatment vs.
brief hospital
intervention
and treatment
referral

Countries

Austria,
RCTs
USA, one
multicounty
trial (Austria,
Canada,
USA)

USA (5
RCTs
studies) and
Iran (1
study)

No. of Included
Findings
Studies
No. of Patients
13 studies
Oral naltrexone did not perform better than
1158 patients treatment with placebo or no agent with respect to
abstinence and relapse, though naltrexone was
favored for number of people reincarcerated.
Naltrexone was not superior to benzodiazepines
and buprenorphine for retention, abstinence, and
side effects, though numbers retained in studies
were generally low. In single study of naltrexone vs.
psychotherapy, there was no statistically significant
difference for abstinence and reincarceration.
Overall, studies inadequate to evaluate oral
naltrexone treatment for opioid dependence.
4 studies
Limited evidence of no significant differences
271 patients between methadone and buprenorphine or slowrelease morphine for all outcomes (child health
status, neonatal mortality, treatment retention, and
reducing substance use)

6 studies
607 patients
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Methadone or buprenorphine appeared equally
effective on opioid use and treatment retention;
Maintenance treatment with buprenorphine
appeared more effective than detoxification or
psychological treatments on opioid use and
treatment retention

Limitations

Focused on effectiveness of medications
/interventions; includes psychotherapy as
an intervention; outpatient trials (unclear if
primary care); 4 trials in USA

Focus on effectiveness of medications; 3
studies in outpatient setting (no further
details); 2 studies done in USA

Use of open label study designs; most
studies conducted in outpatient settings

Author, Year

RahimiMovaghar,
2013128

Intervention
Characteristics

Population
and Setting

Various
OUD due to
pharmacological
heroin;
therapies (alone or in outpatient
combination with
psychosocial
interventions)
compared with no
intervention,
detoxification,
different doses of the
same intervention,
other pharmacologic
interventions and any
psychosocial
interventions; models
of care not described

Countries

Iran

Types of
Studies
Included
RCTs

No. of Included
Findings
Studies
No. of Patients
3 studies
Higher doses of buprenorphine significantly
870 patients increased the treatment retention rate compared
with lower doses; No significant difference in
maintenance retention rate between baclofen vs.
placebo post detoxification.

CCT = controlled clinical trial; LAMM = levo-alpha-acetylmethadol; OUD = opioid use disorder; RCT = randomized controlled trial
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Limitations

Focused on effectiveness of medications;
outpatient setting (unclear if primary
care); no trials in USA (appears Asiafocused)

Guiding Question 4. Future Directions
New and Innovative Strategies
Key Informants uniformly noted that the most promising models of care are those that
emphasize the integration of management of OUD with primary care and other medical and
psychological needs. The chronic disease management paradigm is particularly suitable for
populations with OUD who also have other conditions that require ongoing care, such as HIV or
HCV infection.129 The BHIVES model was specifically designed to integrate office-based
treatment with buprenorphine/naloxone with HIV management. Some important innovations in
implementation of MAT models of care include the use of a nonphysician glue person (e.g.,
OBOT [Yale], Massachusetts Nurse Care Manager model, ECHO Project), integration of more
comprehensive psychosocial services (e.g., One Stop Shop, Medicaid Health Home Model),
coordination and integration of office-based management with centralized centers of excellence
(e.g., Hub and Spoke, Co-OP), and identification and initial treatment in ED, inpatient, or
prenatal settings. Peer-delivered recovery support services are promising and could be integrated
into primary care settings;130 as of 2007, such services are Medicaid reimbursable. Several Key
Informants noted that models of care that also integrate education, training, and outreach, such as
the Massachusetts Nurse Care Manager model, are important for increasing the pool of
buprenorphine-waivered physicians, decreasing stigma, and increasing uptake of MAT, while
also promoting higher-quality care. Existing resources such as PCSS-MAT, which provides
physician training and access to a national network of experts in MAT who can provide
mentoring to those less experienced in prescribing buprenorphine, could be leveraged by models
of care that lack resources for their own educational and training component; such resources
were used successfully in the initial dissemination and expansion of office-based buprenorphine
in the United States. Utilization of existing training and educational resources would also be
more efficient than developing new resources in each implementation setting.
Recent MAT models focus on the identification of patients with OUD and initiation of
treatment in the ED, inpatient, and prenatal settings. These strategies can help identify patients
with OUD who otherwise might not have access to primary care, have a higher prevalence of
OUD (e.g., in the ED and inpatient settings), or facilitate initiation and engagement in treatment.
Ideally, such models of care would be linked to an integrated, office-based model that can
provide ongoing management.
In rural settings, major barriers to MAT include the lack of addiction and psychiatric
expertise, distances that patients must travel to access care, lack of buprenorphine-waivered
physicians, and negative attitudes and beliefs regarding MAT. Strategies to overcome these
barriers include Web-based learning networks (e.g., Project ECHO), use of telemedicine for
consultation with experts, utilization of nonphysician providers in key roles (e.g., screening,
counseling, coordination of care, provision of primary care), and educational and outreach
efforts. In the Southern Oregon Model, for example, local stakeholders meet regularly and
discuss issues in management of OUD and develop practice standards using a collaborative
model. One Key Informant has developed and evaluated computer-assisted delivery of cognitive
behavioral therapy for addiction.131,132 Resources such as these could supplement face-to-face
psychosocial services and would not be constrained by geographical barriers. In rural settings,
the availability of extended-release formulations (e.g., currently approved extended-release
naltrexone and emerging products such as implantable and injectable buprenorphine
preparations) could potentially reduce the need for frequent visits, particularly in less complex
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patients who have long distances to travel, and if coupled with psychosocial services conducted
over the phone or via the Web.
MAT models of care in primary care settings could also integrate pharmacist-based
management strategies. A recent small (n=12 patients) pilot project evaluated a physicianpharmacist collaborative model in which patients were managed using a drug therapy
management model.133 The pharmacist conducted intake assessments and followup appointments
and documented each interaction after debriefing with a physician, who appended additional
notes as needed and cosigned records. The pharmacist was responsible for gathering data from
outside providers and pharmacies regarding prescribed medications and results of urine drug
testing. Prescriptions were written by the physician or called in by the pharmacist. In addition,
the pilot study projected that the model would be cost savings for the health system. Another 2year pilot study in San Francisco evaluated a tiered model with centralized induction and
stabilization followed by management in a community-based center, with buprenorphine dosing
and dispensing provided through a designated pharmacy.134 The pharmacist at the dispensing
pharmacy worked in collaboration with the clinicians at the community center, with a secure
database specifically designed to facilitate communication. However, for both models, details
regarding the provision of psychosocial services and coordination of care within this model are
limited.

Implications for Diffusion of Medication-Assisted Treatment
Key Informants consistently noted that MAT is effective in office-based settings, but access
remains limited, particularly in rural settings. Increasing the number of buprenorphine waivered
physicians as well as the number of buprenorphine waivered physicians who actually prescribe
are critical for increasing the diffusion of MAT. Enhanced use of extended-release naltrexone
could also increase diffusion of MAT since it does not require a waiver to prescribe and provides
patients with additional options. As an opioid antagonist, naltrexone may be preferred by patients
who do not wish to use opioid agonist or partial agonist therapy.
This report describes a number of MAT models of care viewed as effective or promising by
Key Informants. Although evidence is lacking with regard to how one model of care performs
compared with another, comparative effectiveness research may not be the most important
determinant for informing further diffusion of MAT. Rather, the most effective model of care is
likely to depend in part on the specific implementation setting, including unique characteristics
of the target patient population (e.g., HIV infection, pregnant, or adolescent), what resources are
available locally, and financing options. Implementation of the Hub and Spoke or Co-OP
models, for example, requires a relatively local center of expertise in addiction that is willing to
partner with community centers in an integrated model. A model developed for patients with
HIV infection requires expertise in both OUD and HIV care. In rural settings, models of care that
integrate Web-based training, consultation, and mentorship may be needed to overcome the lack
of local expertise. One support model, for example, is the Oregon Addiction Education and
Prevention Initiative, in which academic medical center addiction medicine specialists partner
with accountable care organizations to conduct DATA 2000 waiver training for rural primary
care providers, who are then linked to PCSS and offered personal ongoing phone consultation
support in MAT management. In some cases, effective diffusion of MAT may involve adaptation
of an established model of care to the needs of the particular setting. For example, the
Massachusetts Nurse Care Manager model represents an adaptation of the OBOT model
developed at Yale and the BHIVES model represents an adaptation of the OBOT model for
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patients with OUD and HIV infection. Models of care could also integrate models that target
different parts of the treatment process. For example, models that involve ED or inpatient
screening for OUD and initiation of treatment could be integrated with models that provide
ongoing care based on the Massachusetts Nurse Care Manager or Hub and Spoke models.
Given the barriers to implementing MAT in primary care settings, effective strategies for
implementation are likely to require multifactorial interventions that involve partnerships
between payers and clinics that use financing, contracting, policy change, process improvement
to improve workflow, and customer input to facilitate organizational change. Although one such
intervention (Advancing Recovery) has been shown to increase access to MAT in addiction
treatment settings,135 studies on the effects of Advancing Recovery in primary care settings are
not yet available. Several Key Informants also commented that with increased diffusion of MAT
comes the possibility for suboptimal provision of care. They noted the need for clear standards to
measure the quality of care and ensure that care is adequate. Key Informants also noted that there
is a general lack of knowledge regarding treatment of addiction in primary care, and that
dissemination of addiction education into primary care could help with diffusion of MAT in
primary care.

Ethical, Equity, and Cost Issues
Key Informants noted equity issues with regard to access to MAT in rural areas due to lack
of prescribing physicians, ongoing stigma, and lack of policy and funding support. Efforts to
expand MAT in Medicaid programs and Federally Qualified Health Centers represent an
opportunity to increase equity. Although evidence indicates that OUDs often begin during
adolescence, no models of care have been developed to address adolescent populations.136 A
multi-site clinical trial documented improved short-term outcomes for adolescents and young
adults supported on buprenorphine/naloxone compared with those who completed a brief
taper.122
Key Informants consistently noted that MAT is effective when, and it is important from an
ethical standpoint that, patients have access to these treatments and be provided with accurate
information about the risks and benefits of MAT and alternative treatments. Although substance
use disorder benefits are included as Essential Health Benefits in the Affordable Care Act,
insurers may try to avoid paying for MAT medications through onerous prior authorization
requirements or arbitrarily limit the duration or dose of therapy.137 Key Informants noted that
prevention of buprenorphine diversion has been a major concern of some payers and providers
and in some cases has impacted the ability to provide MAT, due to the effects of efforts to
prevent diversion.
Financing remains a major issue in many settings. They noted that some models have been
run largely by volunteers or are unable to remain financially viable due to inadequate
reimbursement and a lack of state or other financial support. One Key Informant noted that some
private clinics have gone bankrupt trying to work with Medicaid. Some Key Informants noted
that the 100-patient limit for prescribing buprenorphine may make provision of MAT
noneconomically viable for some physicians. Other Key Informants noted that some for-profit
clinics involve several physicians banding together to increase the number of patients treated and
increase economic viability, but this could result in provision of MAT which may not meet
quality of care standards. Key Informants noted that showing that MAT is cost-effective or even
cost-savings in the long run would be very helpful for convincing policymakers and clinicians to
support and use MAT.
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Areas of Uncertainty and Future Research Needs
Based on our review of the literature and Key Informant input, we identified a number of
important areas of uncertainty regarding MAT that warrant additional research. These include:
• Research to identify factors associated with high-quality care and how to measure it.
With improved access to MAT, it is also critical to insure that the quality of care that is
delivered is high. This will require development of new quality of care indicators for use
of MAT in primary care settings.
• Research on management of patients with OUD and concomitant chronic noncancer or
cancer pain,138,139 benzodiazepine use, and/or alcohol use disorder (e.g., use of
buprenorphine/naloxone for transitioning off high doses of opioids in patients with
chronic pain). Treatment of OUD in patients who also have pain is a major challenge
given the high prevalence of opioid prescribing. A systematic review of 10 studies of
limited quality evaluated the role of buprenorphine for management of chronic pain, but
only one study was conducted in primary care.140
• Research on effectiveness of MAT in patients with prescription OUD. Most research on
MAT has focused on patients with heroin use disorder. Research would be helpful for
determining the degree to which evidence on MAT for heroin use disorder can be
extrapolated to those with prescription OUD.
• Research on effectiveness and safety of mid-level prescribing of buprenorphine, such as
by nurse practitioners and physician assistants. Currently, DATA 2000 only permits
physicians to prescribe buprenorphine for OUD. Allowing mid-level providers to
prescribe buprenorphine could help improve access in rural areas with few or no
physicians.
• Research to identify patients more likely to benefit from more intensive psychosocial
services, and methods for effectively targeting specific types of psychosocial services.
The need for more intensive psychosocial services is likely to vary. Understanding which
patients require which services would be very helpful for designing and implementing
effective models of care.
• Research on effectiveness of peer-delivered support services as part of MAT in primary
care settings.130
• Research to understand optimal methods for coordination and integration of care.
Although Key Informants consistently noted that this is a critical component of
successful MAT models of care, methods for coordination and integration of care varied
among models and no study evaluated the effectiveness of different coordination and
integration methods.
• Research to better understand the costs and cost-effectiveness of implementing MAT
models of care. Although long-term treatment with buprenorphine/naloxone in officebased settings appears to be cost-effective141 and provision of MAT using the Hub and
Spoke model in Vermont is associated with decreased health care utilization and costs
than treatment of OUD without medication,142 there are relatively few cost- and costeffectiveness studies and analyses have not compared different MAT models of care or
evaluated the use of newer pharmacological therapies. Such research would be of
particular importance for policymakers, and that such research should address societal
outcomes impacted by OUD (e.g., ability to work, criminal activity) in addition to
impacts on drug use.
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•

•
•

•

•

•

•

•

Research on effective methods implementation of MAT models of care in primary care
settings and increasing uptake of MAT. Although some multicomponent implementation
strategies appear to be effective for enhancing access, they have not yet been studies in
primary care settings.135
Research to better understand optimal duration and doses of treatment. This is
particularly important because otherwise payers may (and sometimes do) impose
arbitrary duration limits for MAT.
Research on effectiveness of telehealth and Web-based training, mentoring, and
educational resources. These would be particularly useful in rural and other settings
where addiction and other expertise are not available locally. As noted elsewhere in this
report, one Key Informant described a Web-based cognitive-behavioral resource that has
been developed131,132,143 and another described psychiatric consultation using computer
tablets.
Research on effectiveness of alternative medications or formulations (e.g., implantable
and injectable buprenorphine preparations). Such formulations could reduce the
frequency of followup, increase uptake and compliance, and mitigate barriers related to
long travel distance. However, there is almost no evidence on injectable buprenorphine
used in primary care settings.
Research on effectiveness of methods for reducing diversion (e.g., use of extendedrelease medications, thrice weekly observed dispensing, or pharmacy-based dispensing).
Pharmacy-based dispensing is done in Canada and Europe for buprenorphine and
methadone prescribed in primary care and has been piloted in small studies in the United
States.133,134 Key Informants noted that preventing diversion has been a major concern of
some payers and policymakers.
Research to understand why buprenorphine waivered physicians don’t prescribe, factors
associated with prescribing, and methods to increase prescribing. The gap between the
number of waivered physicians and the number prescribing indicates that that there is
substantial untapped capacity to prescribe buprenorphine.92
Research to better understand patients who are appropriate for office-based treatment
versus those who require treatment in an OTP. Key Informants noted that current
methods to determine who is appropriate for office-based treatment are largely based on
anecdotal experience.
Research on patients who are more likely to benefit from extended-release naltrexone,
comparative effectiveness of buprenorphine/naloxone versus extended-release
naltrexone, and optimal models of care for provision of extended-release naltrexone.
Most models of care have focused on provision of buprenorphine/naloxone, and there is
very little evidence on use of extended-release naltrexone in primary care settings.
Although there is evidence supporting the efficacy of extended-release naltrexone, Key
Informants reported the perception that this treatment was not in high demand by patients
and that some patients might not do well with opioid antagonist therapy. In addition, a
recent study found a low rate of linkage to ongoing treatment with extended-release
naltrexone following an initial injection during inpatient opioid detoxification.144 On the
other hand, expanding the medication choices for patients could increase uptake and that
extended-release naltrexone may be associated with less stigma by some patients and
providers.
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•

•

Research on effectiveness of methadone for office-based treatment. Methadone is not
authorized under DATA 2000 but has been evaluated in office-based settings in some
clinical trials118,119 and observational studies in the United States,145-147 and is used in
primary care settings in other countries. Primary care providers in Canada, parts of
Europe, and some other countries prescribe methadone for directly observed daily
dispensing in local pharmacies. This model has not been tested in the United States, but
could expand access to OUD treatment while limiting diversion.
Research to understand optimal MAT models of care in adolescents and children,122,136
who often differ from adults in their treatment needs.148 In 2014, an estimated 18,000
adolescents had heroin use disorder and 168,000 had OUD related to prescription
opioids,3 but data indicate that treatment for OUD is markedly underused in this
population.149

Ongoing Studies
We identified several ongoing randomized trials of MAT models of care in primary care
settings that may address some of the research gaps described above (Table 6). One ongoing trial
compared effects of an organizational readiness intervention (including implementation tools and
activities) plus an integrated collaborative care service delivery intervention (based on a chronic
care model) versus usual care for implementing substance use disorder treatment in primary
care.150 Two ongoing trials focused on MAT models of care that involve screening and initiation
of MAT in emergency department151 or inpatient152 settings. One other trial compared effects of
group visits (5 to 10 patients with primary care provider and behavioral specialists) versus usual
care (individual visits) in patients receiving buprenorphine/naloxone.153 Another trial compared a
strategy of an interim bridging buprenorphine treatment intervention for patients on a waitlist for
MAT.154 An AHRQ-funded demonstration project is focused on improving access to MAT in
rural primary care practices.155
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Table 6. Ongoing studies of MAT for OUD
Reference
Bogenschutz, M. Comparing interventions
for opioid dependent patients presenting in
medical emergency departments.
https://clinicaltrials.gov/ct2/show/NCT02586
896?term=NCT02586896&rank=1151

Setting
Opioid dependent
patients in medical
emergency
departments

Study design, Interventions
RCT
Brief strengths-based case management vs.
screening, assessment and referral alone

Fox, A. Buprenorphine group medical visits
in primary care.
https://clinicaltrials.gov/ct2/show/NCT02526
212?term=NCT02526212&rank=1153
Group Buprenorphine Maintenance
Treatment (G-BMT) Study

Primary care

Ober, AJ. An organizational readiness
intervention and randomized controlled trial
to test strategies for implementing
substance use disorder treatment into
primary care: SUMMIT study protocol.
http://www.ncbi.nlm.nih.gov/pmc/articles/P
MC4432875/150
Watkins, K. Integrated collaborative care for
substance use disorders.
https://clinicaltrials.gov/ct2/show/NCT01810
159156
Substance Use Motivation Medication
Integrated Treatment (SUMMIT) Study

Federally-qualified
health center and
Venice Family Clinics

RCT
Group visits (90 minutes; 5-10 patients
simultaneously receive care from a multidisciplinary
team of a generalist physician and a behavioral
specialist) vs. treatment as usual in primary care
(individual visits including protocol of BMT
intensification, which includes increased visit
frequency, referral for mental health counseling, and
referral to addiction treatment specialist); both
buprenorphine
RCT
Integrated collaborative care vs service as usual
Details: combined effect of both an organizational
readiness intervention, consisting of implementation
tools and activities and an integrated collaborative
care service delivery intervention, based on the
Chronic Care Model
Also, mixed methods study (pre-post analysis)

Sigmon, S. Interim buprenorphine:
leveraging medication and technology to
bridge delays in treatment access (IBT).
https://clinicaltrials.gov/ct2/show/NCT02360
007154

Patients on a waitlist
for clinic treatment
placement

RCT
Strategy of an interim bridging buprenorphine
treatment intervention for patients on a waitlist for
MAT including buprenorphine, computerized
adherence monitoring, mHealth clinical support
delivered via interactive voice response, automated
random call-backs for urinalysis and adherence
monitoring, and HIV and hepatitis education
delivered via iPad vs. waitlist control condition
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Outcomes
Initiation of and engagement in
treatment for opioid dependence
Opioid and other substance use
Initiation and engagement in
participants with higher levels of
environmental instability at baseline
Quality of life
Opioid abstinence
Retention in treatment
HIV risk behaviors
Acceptability
Feasibility

Service system outcomes: patientcentered care, utilization of substance
use disorder treatment, utilization of
health care services and adoption and
sustainability of evidence-based
practices
Patient outcomes: substance use,
consequences of use, health and
mental health, and satisfaction with care

Illicit opioid abstinence
Addiction severity index subscale
scores

Reference
Setting
Study design, Interventions
Stein, M. Linking opioid-dependent patients Recruiting illicit opioid
RCT
from inpatient detoxification to primary care. users during
Buprenorphine, initiated during inpatient
https://wwwcf.nlm.nih.gov/hsr_project/view_ detoxification and
detoxification and continued after discharge vs.
hsrproj_record.cfm?NLMUNIQUE_ID=2013 linking them to primary buprenorphine detoxification
2453&SEARCH_FOR=(((%22primary%20c care-based treatment
are%22))%20AND(buprenorphine))%20OR
(naltrexone)152
MAT = medication-assisted treatment; OUD = opioid use disorder; RCT = randomized controlled trial
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Outcomes
Illicit opioid use
Emergency department and hospital
utilization

Summary and Implications
A number of MAT models of care have been developed and implemented in primary care
settings. Key Informants noted that MAT models of care could be described using a framework
focusing on the following four components: (1) pharmacological therapy; (2) psychosocial
services; (3) integration of care; and (4) education and outreach. This report describes 12
representative/key models of care utilizing a framework based on these four components.
Although other models of care have been developed, in many cases sources to understand their
components could not be identified, or it was difficult to determine how they differed from the
representative models. A challenge in understanding current MAT models of care is the limited
published data on most models. No study has compared the effectiveness of one MAT model of
care in primary care versus another; rather, most trials have focused on specific components, in
particular which medication was used and the type of psychosocial services provided. However,
the ideal model of care for a particular setting is likely to depend on a number of local factors,
such as the expertise available, the population being served, proximity to an addiction center of
excellence, reimbursement policies, geographic factors, and others. Several Key Informants
noted that efforts to implement MAT have often failed due to poor reimbursement or because the
model was financially unsustainable for other reasons. Therefore, decisions about MAT models
of care may best be individualized to address the unique milieu of each implementation setting.
In some situations, it may be appropriate to use elements of different models of care (e.g.,
implement nurse care manager-based coordination of care within a Hub and Spoke model of
care) or to link models of care (e.g., ED or inpatient based screening and initiation of treatment
linked with an office-based model of care for ongoing management).
Regarding the pharmacological therapy component, most MAT models of care in primary
care settings to date have focused on provision of sublingual buprenorphine/naltrexone.
Although implantable buprenorphine was approved by the FDA in 2016, research on its use in
primary care settings is lacking. Similarly, although extended-release naltrexone has been shown
to be effective in addiction treatment settings, research on its use in primary care settings is
extremely sparse. Provision of additional pharmacological therapy choices for MAT has
potential advantages in terms of expanding patient choices, reducing risk of diversion, and
decreasing need for frequent followup in appropriate patients.
Key Informants consistently noted that the psychosocial services component is critical for
any MAT model of care, but there is uncertainty about whether brief counseling (as required by
DATA 2000) is sufficient, or whether more extensive psychosocial services should be routinely
available. In addition, many different types of psychosocial services beyond brief counseling are
available and it is uncertain which services should be prioritized when implementing a model of
care. Although most evidence suggests that more intensive psychosocial services are not
associated with superior outcomes to standard counseling, Key Informants noted that some
patients require more intensive psychosocial services and that research is needed to identify
higher-risk patients who would benefit from such services. Although Key Informants generally
agreed that psychosocial services are best provided on-site, some models of care use services via
an affiliated OTP or through telehealth/Web-based resources.
A core component of successful MAT models of care is the integration/coordination
component, in order to manage issues related to OUD as well as psychological, medical, and
primary care needs. Key Informants viewed successful integration of care as critical for the
success of any MAT model of care. The MAT models of care that were viewed as particularly
successful used a designated nonphysician staff member in the integration/coordination role,
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reducing the burden on the physician while increasing practice efficiency and permitting more
patients to be effectively and safely treated.
Although the education and outreach component was not as well-defined in some models,
this was viewed by Key Informants as critical for reducing stigma associated with MAT,
increasing the pool of prescribing physicians, and increasing uptake, particularly in settings in
which stigma is still high. Education was also viewed as critical for improving standards and
quality of care. Our survey of MAT models of care indicated a number of approaches to
education and outreach, including a Web-based learning network and educational resources,
internet-based mentoring by more experienced physicians, meetings of community stakeholders,
in-person educational sessions with patient and clinician educational sessions, and others.
Particular challenges in rural settings include a lack of waivered buprenorphine physicians,
limited access to addiction expertise, persistent stigma associated with MAT, and long travel
times for patients. Models of care developed in rural settings have attempted to address some of
these issues by utilizing a Web-based learning network and accessing a national network of
mentoring physicians. Other strategies that could be helpful include use of longer-acting
medication formulations to reduce the number of followup visits in appropriate patients, use of
telemedicine, engagement of community stakeholders, use of online interventions such as Webbased cognitive-behavioral therapy, and use of mid-level providers for administration of MAT.
We identified a number of important areas of uncertainty with regard to MAT models of
care in primary care settings, including methods for measuring quality of care, how to assess
patients to better individualize care, optimal psychosocial components of MAT,
effectiveness of mid-level prescribing, enhancing access to and uptake of MAT in primary
care settings, effectiveness of newer or alternative medications for OUD, optimal
medications dosing strategies, cost and cost effectiveness, methods for reducing diversion,
effective implementation methods, optimal methods for coordination and integration of care,
and effectiveness of telehealth and telemedicine approaches. Research in these areas would
be helpful for informing future efforts at dissemination and expansion of MAT in primary
care settings. In the meantime, this technical brief describes a number of MAT models of
care that have been developed and implemented in such settings, which may help inform
further efforts at individualized implementation of MAT.
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Appendix A. Sample Questions for Key Informants
Key Informant
Perspective
Researchers and
Clinicians (including
Professional
Societies and
Organizations)

Sample Questions
Guiding Questions 1, 2, and 4.

In addition:
1. What outcomes should be prioritized?
2. In your experience, what MAT models of care have been particularly successful and why?
3. Are there models of care that are particularly suited (e.g., feasibility, applicability) for rural
or other underserved settings?
4. How would you categorize the components of MAT models of care?
5. What MAT models of care components are most critical for effectiveness?
6. What are barriers to implementation of MAT in primary care settings?
7. What are specific barriers to implementation of community-based psychosocial programs in
MAT?
8. How could barriers to implementation be overcome?
9. Are you aware of new or innovative models of care that warrant additional research?
10. What are key research needs to understand effectiveness and implementation of MAT
models of care?
11. What types of study designs would be useful for studying new or innovative MAT models
of care?
12. What is a meaningful length of followup?
13. Are there specific areas related to effectiveness or implementation of MAT models of care
that have been sufficiently studied to warrant a systematic evidence review?
Health Policy and
1. What outcomes of MAT are important from a health policy/payer perspective?
Implementation
2. What policies do payers put in place to influence use of MAT for treatment of opioid use
Arenas
disorder?
3. How are decisions to cover or implement MAT made at a policy level or at an
institutional/clinical setting level?
4. What are some research questions about MAT that you would like answered to inform
policy and implementation decisions?
5. Are you considering new policies to improve the use of MAT, particularly in primary care,
including rural or other underserved populations?
6. What are cost and/or economic efficiency considerations that impact diffusion, decisionmaking, and/or conceptual thinking around MAT?
Patient Perspective
1. What values do patients place on various non-substance-use-related outcomes and how
do patients weigh trade-offs related to different pharmacological and non-pharmacological
approaches?
2. What factors or themes are most important to patients receiving MAT?
3. What components of MAT are important for patients to know, that they may not be aware
of?
4. What common experiences do patients in MAT programs describe?
5. Should the use of MAT programs be expanded; and if so, what settings for patients are
most amenable to the implementation of MAT?
6. What barriers do patients experience in obtaining MAT?
7. What suggestions do patients have for improving MAT models of care?
8. What are ethical, privacy, equity, or cost considerations that impact patient’s use of MAT?
MAT = medication-assisted treatment
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Appendix B. Search Strategies for Guiding Question 3
Database: Ovid MEDLINE
1 exp Opiate Substitution Treatment
2 exp Opioid-Related Disorders/dt, pc, px, rh, th
3 methadone.mp. or exp Methadone
4 buprenorphine.mp. or Buprenorphine
5 naltrexone.mp. or Naltrexone
6 suboxone.mp.
7 3 or 4 or 5 or 6
8 2 and 7
9 (medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or program*)).mp. [mp=title, abstract,
original title, name of substance word, subject heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique identifier]
10 ((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2 (treatment* or therap* or regimen*
or program* or interven*)).ti,ab.
11 9 or 10
12 2 and 11
13 1 or 8 or 12
14 limit 13 to english language
15 exp Comprehensive Health Care/
16 exp Community Health Services/
17 exp Outpatients/
18 exp Ambulatory Care/
19 exp Ambulatory Care Facilities/
20 exp General Practice/
21 general practitioners/ or physicians, family/ or physicians, primary care/
22 exp Health Services Accessibility/
23 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24 (((primary or ambulatory) adj3 care) or ((family or general) adj3 (medicine or practice* or physician* or doctor*
or practitioner* or provider*)) or outpatient* or ((communit* or comprehensiv*) adj3 (health* or care))).mp.
25 (rural* or underserv* or frontier* or (geograph* adj3 (isolat* or remot*))).mp. [mp=title, abstract, original title,
name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare
disease supplementary concept word, unique identifier]
26 24 or 25
27 23 or 26
28 14 and 27
29 limit 28 to yr="2005 -Current"
30 limit 28 to yr="1902 - 2004"
31 limit 14 to systematic reviews
32 limit 14 to (controlled clinical trial or guideline or randomized controlled trial)
33 exp epidemiologic study/
34 14 and 33
35 Comparative Study/
36 14 and 35
37 exp "Outcome and Process Assessment (Health Care)"/
38 14 and 37
39 mo.fs.
40 exp Death/
41 exp Vital Statistics/
42 39 or 40 or 41
43 14 and 42
44 exp Evaluation Studies as Topic/
45 14 and 44
46 exp "costs and cost analysis"/
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47 14 and 46
48 exp Sociological Factors/
49 14 and 48
50 exp quality of life/
51 14 and 50
52 exp health behavior/
53 14 and 52
54 exp attitude to health/
55 14 and 54
56 31 or 32 or 34 or 36 or 38 or 43 or 45 or 47 or 49 or 51 or 53 or 55
57 28 or 56
Database: EBM Reviews - Cochrane Database of Systematic Reviews
1 [exp Opiate Substitution Treatment/]
2 [exp Opioid-Related Disorders/dt, pc, px, rh, th]
3 methadone.mp. or exp Methadone/
4 buprenorphine.mp. or Buprenorphine/
5 naltrexone.mp. or Naltrexone/
6 suboxone.mp.
7 3 or 4 or 5 or 6
8 2 and 7
9 (medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or program*)).mp.
10 ((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2 (treatment* or therap* or regimen*
or program* or interven*)).ti,ab.
11 9 or 10
12 1 or 8 or 11
Database: EBM Reviews - Cochrane Central Register of Controlled Trials
1 exp Opiate Substitution Treatment/
2 exp Opioid-Related Disorders/dt, pc, px, rh, th
3 methadone.mp. or exp Methadone/
4 buprenorphine.mp. or Buprenorphine/
5 naltrexone.mp. or Naltrexone/
6 suboxone.mp.
7 3 or 4 or 5 or 6
8 2 and 7
9 (medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or program*)).mp.
10 ((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2 (treatment* or therap* or regimen*
or program* or interven*)).ti,ab.
11 9 or 10
12 1 or 8 or 11
Database: PsycINFO
1 exp opiates/
2 exp drug rehabilitation/
3 exp drug dependency/
4 2 or 3
5 exp drug therapy/
6 exp methadone maintenance/
7 methadone.mp. or exp Methadone/
8 buprenorphine.mp. or Buprenorphine/
9 naltrexone.mp. or Naltrexone/
10 suboxone.mp.
11 5 or 6 or 7 or 8 or 9 or 10
12 1 and 4 and 11
13 (medicat* adj3 assist* adj3 (treat* or therap* or regimen* or interven* or program*)).mp.
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14 ((opiate* or opioid* or narcotic*) adj2 (substitut* or replac* or maint*) adj2 (treatment* or therap* or regimen*
or program* or interven*)).ti,ab.
15 13 or 14
16 1 and 4 and 15
17 12 or 16
18 limit 17 to english language
19 exp Primary Health Care/
20 exp community services/
21 exp Outpatients/
22 exp outpatient treatment/
23 exp Maintenance Therapy/
24 exp Ambulatory Care/
25 exp Ambulatory Care Facilities/
26 exp General Practitioners/
27 exp Family Medicine/
28 exp Family Physicians/
29 exp Treatment Barriers/
30 exp health disparities/
31 exp health care utilization/
32 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31
33 (((primary or ambulatory) adj3 care) or ((family or general) adj3 (medicine or practice* or physician* or doctor*
or practitioner* or provider*)) or outpatient* or ((communit* or comprehensiv*) adj3 (health* or care))).mp.
34 (rural* or underserv* or frontier* or (geograph* adj3 (isolat* or remot*))).mp.
35 33 or 34
36 32 or 35
37 18 and 36
38 limit 18 to systematic reviews
39 exp treatment outcomes/ or exp treatment effectiveness evaluation/
40 18 and 39
41 exp "Death and Dying"/
42 exp mortality rate/
43 41 or 42
44 18 and 43
45 exp "costs and cost analysis"/
46 18 and 45
47 exp Sociocultural Factors/
48 exp socioeconomic status/
49 47 or 48
50 18 and 49
51 exp quality of life/
52 18 and 51
53 exp health behavior/
54 18 and 53
55 exp attitudes/
56 18 and 55
57 38 or 40 or 44 or 46 or 50 or 52 or 54 or 56
58 37 or 57
CINAHL
S1 (MH "Substance Use Disorders+")
S2 (MH "Narcotics+")
S3 S1 AND S2
S4 "methadone"
S5 "buprenorphine"
S6 "naltrexone"
S7 suboxone
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S8 S4 OR S5 OR S6 OR S7
S9 S1 AND S8
S10 (medicat* n3 assist* n3 (treat* or therap* or regimen* or interven* or program*))
S11 ((opiate* or opioid* or narcotic*) n2 (substitut* or replac* or maint*) n2 (treatment* or therap* or regimen* or
program* or interven*))
S12 S10 OR S11
S13 S1 AND S12
S14 S3 OR S9 OR S13
S15 S3 OR S9 OR S13
S16 (MH "Primary Health Care")
S17 (MH "Community Health Services+")
S18 (MH "Outpatients") OR (MH "Outpatient Service") OR (MH "Ambulatory Care Facilities+")
S19 (MH "Family Practice")
S20 (MH "Physicians, Family")
S21 (MH "Health Services Accessibility+")
S22 S16 OR S17 OR S18 OR S19 OR S20 OR S21
S23 (((primary or ambulatory) n3 care) or ((family or general) n3 (medicine or practice* or physician* or doctor* or
practitioner* or provider*)) or outpatient* or ((communit* or comprehensiv*) n3 (health* or care)))
S24 (rural* or underserv* or frontier* or (geograph* n3 (isolat* or remot*)))
S25 S23 OR S24
S26 S22 OR S25
S27 S15 AND S26
S28 (MH "Systematic Review")
S29 (MH "Meta Analysis")
S30 (MH "Practice Guidelines") OR (MH "Guideline Adherence")
S31 (MH "Randomized Controlled Trials")
S32 (MH "Epidemiological Research+")
S33 (MH "Prospective Studies+")
S34 S28 OR S29 OR S30 OR S31 OR S32 OR S33
S35 S15 AND S34
S36 (MH "Outcomes (Health Care)+")
S37 (MH "Vital Statistics+")
S38 (MH "Evaluation Research+")
S39 (MH "Costs and Cost Analysis+")
S40 (MH "Socioeconomic Factors+")
S41 (MH "Cultural Values")
S42 (MH "Quality of Life+")
S43 (MH "Quality-Adjusted Life Years")
S44 (MH "Health Behavior+")
S45 (MH "Attitude+")
S46 S36 OR S37 OR S38 OR S42 OR S43
S47 S15 AND S46
S48 S15 AND S46
S49 S15 AND S34
S50 s48 NOT s49
SocINDEX
S1 (MH "Substance Use Disorders+")
S2 (MH "Narcotics+")
S3 S1 AND S2
S4 "methadone"
S5 "buprenorphine"
S6 "naltrexone"
S7 suboxone
S8 S4 OR S5 OR S6 OR S7
S9 S1 AND S8
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S10 (medicat* n3 assist* n3 (treat* or therap* or regimen* or interven* or
program*))
S11 ((opiate* or opioid* or narcotic*) n2 (substitut* or replac* or
maint*) n2 (treatment* or therap* or regimen* or program* or interven*))
S12 S10 OR S11
S13 S9 OR S12
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Appendix C. Literature Flow Diagram for Guiding
Question 3
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Appendix F. Details of Trials for Guiding Question 3
Model name
Author, year

Comparators

Duration of N
Followup

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

Types of Outcomes and
Harms Examined and
How They Were
Measured

Findings

USA; 76.3%
male; 75.4%
white; mean age
31.4 years (SD
10.6); study done
in USA; 34.3%
use alcohol to
intoxication;
47.4% used
sedatives in past
month; 52.9%
used cannabis in
past month;
55.3% used
cocaine in past
month; 88.1%
used cigarettes in
past month;
51.1% had
received
psychiatric
treatment in the
past; 26.1% had
received inpatient psychiatric
treatment; 41.9%
had received outpatient psychiatric
treatment; 12.2%
had received
treatment for
depression in the
past month;
24.9% used
prescription
opioids; 75.1%
used heroin;
52.9% were IV
drug users

Buprenorphine group given
treatment for 10 weeks before
transferred to community
program or detoxification for 2
weeks; Referral group received
information for treatment
programs only; brief
intervention program received
a brief 10- to 15-minute
manual-driven audio-taped
brief negotiation interview from
a research associate who
linked them with a referral;
buprenorphine group received
a Brief Negotiation Interview
and if they exhibited moderate
to severe opioid withdrawal
received ED-initiated treatment
and sufficient take-home daily
doses to get through to next
appointment, those without
opioid withdrawal were given
unobserved inducted with
detailed self-medication guide,
then office based
buprenorphine treatment, and
ongoing opioid agonist
maintenance treatment or
detoxification

Urban teaching
hospital; Research
associate performed ED
visits, interviews, and
referrals. Physicians
and nurses managed
buprenorphine dosages

Engagement in treatment
assessed by direct contact
with the facility, clinicians,
or both; self-reported
number of days of illicit
opioids use in the past 7
days; urine toxicology for
illicit opioid use; HIV risktaking behavior using an
11-item validated scale for
drug use and sexual
behavior; and use of
addiction treatment
services.

Among opioid-dependent
patients, ED-initiated
buprenorphine treatment
vs brief intervention and
referral significantly
increased engagement in
addiction treatment,
reduced self-reported illicit
opioid use, and decreased
use of inpatient addiction
treatment services but did
not significantly decrease
the rates of urine samples
that tested positive for
opioids or of HIV risk.
These findings require
replication in other centers
before widespread
adoption.

MAT Models of
Care
D'Onofrio, 20151

Screening and referral 30 days
to treatment (referral)
vs. screening, brief
intervention, and
facilitated referral to
community-based
treatment services
(brief intervention) vs.
screening, brief
intervention, EDinitiated treatment with
buprenorphine/naloxon
e, and referral to
primary care for 10week followup
(buprenorphine)

329

F-1

Model name
Author, year

Comparators

Duration of N
Followup

Fiellin, 20022

Buprenorphine and
13 weeks
medication
management (thriceweekly sessions with a
nurse and a monthly
meeting with a
physician) vs.
buprenorphine and
medication
management plus drug
counseling (not
described)

14

Population
Characteristics

Specifics of Model
Components/
Implementation

USA; 71% male;
93% white, mean
age 36 years;
50% current IV
drug user; mean
7 years heroin
use; 79% with
history/current
alcohol
dependence;
79% with
history/current
cocaine
dependence

Buprenorphine given 3 times
per week following one week
induction with dose escalation
as needed for positive urine
screen or withdrawal.
Medication management group
had brief monthly counseling
sessions with physicians and 3
times per week manual-guided
counseling sessions with
nurses covering recent drug
use, abstinence efforts,
attendance at self-help groups
with support and advice for
efforts to reduce drug use or
remain abstinent.
Medication management plus
manual-guided drug
counseling sessions met
weekly (no details provided)

F-2

Setting/ Provider
Type/ Staffing

Types of Outcomes and
Harms Examined and
How They Were
Measured
Urban academically
Illicit drug use: urine
affiliated medical
toxicology and self report
center; primary care;
Retention/adherence:
medical management
attendance at visits
provided by nurses and Overall health:SF-36
physicians (counseling Patient satisfaction
issues reviewed weekly
with physician and
clinical psychologist)

Findings

Overall, patients reduced
opioid-positive urine
toxicology tests and good
retention through
maintenance; less
patients in medication
management group vs.
medication management
plus counseling group
achieved greater than or
equal to one week of
opioid-free urine screens,
though this difference was
not statistically significant;
A greater proportion of the
medication management
plus counseling group had
opioid-free urine screens
compared with the
medication management
alone group, though this
difference was not
statistically significant

Model name
Author, year

Comparators

Duration of N
Followup

Population
Characteristics

Fiellin, 20063

Standard medical
24 weeks
management (20
minutes with a nurse)
and once-weekly
medication dispensing
(buprenorphinenaloxone) vs. standard
medical management
and thrice-weekly
medication dispensing
vs. enhanced (45
minutes with a nurse)
medical management
and thrice-weekly
medication dispensing
All groups met monthly
with a physician

166

USA; 78% male;
77% white; mean
age 36 years;
mean duration of
opioid
dependence 8
years; 17%
prescription drug
use; 31% history
of intravenous
drug use; 20%
cocaine-positive
urine specimen at
treatment entry;
66% previously
attempted
detoxification;
32% history of
participation in
methadonemaintenance
program

6 months
Liebschutz, 20144 Detoxification plus
referral vs. induction
plus contact from longterm opioid agonist
treatment staff that
facilitated linkage to
hospital-associated
primary care
buprenorphine
treatment

139

USA; 71.2%
male; mean age
40.5 (SD 11.8);
mean illicit opioid
use per 30
followup days
20.8 (SD 9.7)

Specifics of Model
Components/
Implementation

Types of Outcomes and
Harms Examined and
How They Were
Measured
Nurses dispensed
Trained primary care
Illicit opioid use: urine
buprenorphine-naloxone and nurses without previous toxicology and self-report
provided standard (20 minutes; addiction treatment,
Abstinence: measured in
sessions covered recent drug physician, psychologist consecutive weeks
use or efforts to achieve or
Primary care center
maintain abstinence,
attendance in self-help groups,
support for efforts to reduce
drug use or remain abstinent,
advice for the achievement or
maintenance of abstinence,
and the results of analysis of
weekly urine specimens) or
enhanced (45 minutes;
sessions covered similar
issues but provided more indepth drug counseling)
medical management
Physicians met with patients
monthly (20 minutes; sessions
paralleled that of the standard
sessions, with the addition of
an assessment of employment,
legal, family or social, medical,
and psychiatric problems
related to addiction)
The nurses, a physician, and a
psychologist met weekly to
review the counseling
Both groups received
Hospital and medical
Entry into opioid agonist
buprenorphine and naloxone
center; Research staff, treatment program, length
up to 4 times for the first day in which included an
of illicit opioid use defined
the hospital. Detoxification
addiction nurse
as number of days of
group received 4 additional
specialist, hospital
reported opioid use in the
30 days before visits, time
days of tapering buprenorphine nursing staff
to entry into buprenorphine
and naloxone, then treatment administered
medication in hospital
program, number of selfreferral information; linkage
reported prescribed opioid
group received buprenorphine
agonist treatment in the 30
and naloxone for
days before visits,
hospitalization with enough
mortality.
given at discharge to get
through to clinic appointment,
before discharge research staff
facilitated linkage to hospitalassociated primary care
buprenorphine treatment

F-3

Setting/ Provider
Type/ Staffing

Findings

The efficacy of brief
weekly counseling and
once-weekly medication
dispensing did not differ
significantly from that of
extended weekly
counseling and
thrice-weekly dispensing

Compared with an
inpatient detoxification
protocol, initiation of and
linkage to buprenorphine
treatment is an effective
means for engaging
medically hospitalized
patients who are not
seeking addiction
treatment and reduces
illicit opioid use 6 months
after hospitalization.
However, maintaining
engagement in treatment
remains a challenge.

Model name
Author, year

Comparators

Duration of N
Followup

Lucas, 20105

Clinic-based, nurse12 months
administered treatment
with buprenorphinenaloxone vs. case
management and
referral to an intensive
opioid treatment
program (referred
treatment)

93

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

USA; 72% male;
98% black;
median ages 4546 years; median
years of opioid
use 18-20 years;
96% heroin used
in previous
month; 27%
prescription
opioid used in
previous month;
72% used
cocaine in
previous month;
60% injection
drug use in
previous month;
73% positive for
hepatitis C
antibody; 10%
AIDS-defining
opportunistic
condition in
previous 3
months; 53%
receiving ART

Clinic-based group was
managed and seen weekly by
a nurse (10-40 minutes;
sessions included unstructured
individual counseling, urine
samples, observed
buprenorphine doses, and
provision of take-home
supplies of buprenorphine to
last until their next visit), and
met with a physician 4-6 weeks
after initiation of therapy and at
other times as indicated. A
treatment team, comprising the
nurse and 2 to 5
buprenorphine prescribing
physicians, met weekly to
discuss participants’ progress
in treatment. The treatment
team set reporting frequencies,
which ranged from 3 times
weekly to monthly, according
to drug test results and other
factors.

Licensed practical
nurse with training and
experience as a
substance counselor,
buprenorphine
prescribing physicians
HIV clinic

Participants assigned to
referred treatment were
enrolled in an intensive case
management program that has
operated in the same clinic. A
social worker or registered
nurse in the case management
program met with referred
treatment participants shortly
after randomization and made
treatment plans that were
primarily focused on linking
participants to opioid treatment
programs, but may have
included such issues as food
and housing needs

F-4

Types of Outcomes and
Harms Examined and
How They Were
Measured
Drug use: urine toxicology
Participation in opioid
agonist therapy at study
visits: self-reported
Also, visits with primary
HIV providers, months of
ART use, changes in HIV
RNA levels and CD4 cell
counts, and proportion of
participants with
emergency department
visits or hospitalizations
(methods NR)

Findings

Participation in opioid
agonist therapy was
significantly higher in
clinic-based
buprenorphine than for
referred treatment.
Positive test results for
opioids and cocaine were
significantly less frequent
in clinic-based
buprenorphine than in
referred treatment, and
study participants
receiving clinic-based
buprenorphine attended
significantly more HIV
primary care visits than
those receiving referred
treatment. Use of
antiretroviral therapy and
changes in HIV RNA
levels and CD4 cell
counts did not differ
between the 2 groups.

Model name
Author, year

Comparators

Duration of N
Followup

Population
Characteristics

Sullivan, 20066

Buprenorphine/
12 weeks
naloxone and
physician management
(brief, biweekly) vs.
buprenorphine/
naloxone and
physician management
plus once-weekly drug
counseling and
adherence
management

16

USA; 94% male;
31% white, 44%
Black, 25%
Hispanic; mean
age 47 years;
mean 17 years
opioid
dependence;
56% with injection
drug use; 29%
reported one or
more days of
alcohol use in
past 30 days;
36% reported one
or more days of
cocaine use in
past 30 days;
100% HIV
positive; mean 13
years since HIV
diagnosis; 63%
currently on ART;
81% HCV
positive

Buprenorphine and
12 weeks
individual counseling
plus contingency
management (based
on urine results linked
to points for gift cards
or money) vs.
buprenorphine and
individual counseling
and contingency
management plus
internet-based
community
reinforcement
approach
Both groups had
individual counseling
every 2 weeks

170

USA; 54% male,
95% white, mean
age 34 years;
13% with
concurrent
alcohol
dependence, 5%
with concurrent
cocaine
dependence,
12% with
concurrent
sedative
dependence,
29% with
concurrent
cannabis
dependence;
46% had prior
treatment; 14%
with injection drug
use

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

Types of Outcomes and
Harms Examined and
How They Were
Measured
Buprenorphine/naloxone
HIV clinics;
Treatment retention
stabilization over 2-weeks with Buprenorphine and
Illicit drug use: urine
clinic visits 3 times per week
physician management toxicology and self-report
and 1 and 2-day take home
provided by physician
Laboratory parameters:
doses then 10-week
specialized in addiction CD4 count, viral load, and
maintenance period with once medicine and
liver function tests
weekly clinic visits and 6 take experienced in HIV
Adherence to MAT and
home doses then offered 2care; drug counseling
ART: Medication Event
week taper or extension
and adherence
Monitoring System (caps
phase; all patients received
management provided that record the date and
brief, bi-weekly, manual-guided by trained nursing staff time the pill bottle was
(issues reviewed with
opened)
physician management that
supervising physician
HIV transmission risk
focused on symptoms, drug
and clinical
behaviors: HIV/AIDS Risk
use, and progress; half of
psychologist)
Inventory
patients received physician
Health status: SF-36
management plus once-weekly
Patient satisfaction: 5-point
drug counseling and
adherence management
Likert scale questionnaire
focused on addiction-specific
topics like triggers,
relationships, and craving and
strategies to increased
adherence to antiretroviral
treatment

Findings

Buprenorphine given 3 times
per week with extra dose for
days in between; contingency
management based on urine
results linked to points for gift
cards or money; community
reinforcement approach
completed set of topics on
community reinforcement
approach at each clinic visit;
both groups had individual
counseling every 2 weeks

Compared to those
receiving contingency
management-alone,
community reinforcement
approach recipients had
more total days of
abstinence and were less
likely to drop out of
treatment; prior treatment
for opioid dependence
moderated the additional
improvement of
community reinforcement
approach for longest
continuous days of
abstinence

There was no difference
in treatment retention or
illicit drug use by
counseling group; Overall,
the proportion of opioidpositive weekly urine
screens decreased
substantially over trial;
CD4 counts remained
stable; viral load declined
significantly;
demonstrated feasibility of
integrating buprenorphine
into HIV clinical care for
treatment of opioid
dependence

Psychosocial
Interventions
Christensen,
20147

F-5

Clinic setting at
university research
center; Buprenorphine
from study physician;
therapist for community
reinforcement approach
and counseling

Retention: number of days
from start of intervention
until participant left trial or
completed trial
Abstinence: number of
negative urine specimens
overall and over longest
continuous period with
missed visits equal to
positive result
Addiction-related severity:
ASI

Model name
Author, year

Comparators

Fiellin, 20022

Buprenorphine and
13 weeks
medication
management (thriceweekly sessions with a
nurse and a monthly
meeting with a
physician) vs.
buprenorphine and
medication
management plus drug
counseling (not
described)

(also a model of
care

Duration of N
Followup

14

Population
Characteristics

Specifics of Model
Components/
Implementation

USA; 71% male;
93% white, mean
age 36 years;
50% current IV
drug user; mean
7 years heroin
use; 79% with
history/current
alcohol
dependence;
79% with
history/current
cocaine
dependence

Buprenorphine given 3 times
per week following one week
induction with dose escalation
as needed for positive urine
screen or withdrawal.
Medication management group
had brief monthly counseling
sessions with physicians and 3
times per week manual-guided
counseling sessions with
nurses covering recent drug
use, abstinence efforts,
attendance at self-help groups
with support and advice for
efforts to reduce drug use or
remain abstinent.
Medication management plus
manual-guided drug
counseling sessions met
weekly (no details provided)
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Setting/ Provider
Type/ Staffing

Types of Outcomes and
Harms Examined and
How They Were
Measured
Urban academically
Illicit drug use: urine
affiliated medical
toxicology and self report
center; primary care;
Retention/adherence:
medical management
attendance at visits
provided by nurses and Overall health:SF-36
physicians (counseling Patient satisfaction
issues reviewed weekly
with physician and
clinical psychologist)

Findings

Overall, patients reduced
opioid-positive urine
toxicology tests and good
retention through
maintenance; less
patients in medication
management group vs.
medication management
plus counseling group
achieved greater than or
equal to one week of
opioid-free urine screens,
though this difference was
not statistically significant;
A greater proportion of the
medication management
plus counseling group had
opioid-free urine screens
compared with the
medication management
alone group, though this
difference was not
statistically significant

Model name
Author, year

Comparators

Fiellin, 20063

Standard medical
24 weeks
management (20
minutes with a nurse)
and once-weekly
medication dispensing
(buprenorphinenaloxone) vs. standard
medical management
and thrice-weekly
medication dispensing
vs. enhanced (45
minutes with a nurse)
medical management
and thrice-weekly
medication dispensing
All groups met monthly
with a physician

(also a model of
care)

Duration of N
Followup

Population
Characteristics

166

USA; 78% male;
77% white; mean
age 36 years;
mean duration of
opioid
dependence 8
years; 17%
prescription drug
use; 31% history
of intravenous
drug use; 20%
cocaine-positive
urine specimen at
treatment entry;
66% previously
attempted
detoxification;
32% history of
participation in
methadonemaintenance
program

Specifics of Model
Components/
Implementation

Types of Outcomes and
Harms Examined and
How They Were
Measured
Nurses dispensed
Trained primary care
Illicit opioid use: urine
buprenorphine-naloxone and nurses without previous toxicology and self-report
Abstinence: measured in
provided standard (20 minutes; addiction treatment,
sessions covered recent drug physician, psychologist consecutive weeks
Primary care center
use or efforts to achieve or
maintain abstinence,
attendance in self-help groups,
support for efforts to reduce
drug use or remain abstinent,
advice for the achievement or
maintenance of abstinence,
and the results of analysis of
weekly urine specimens) or
enhanced (45 minutes;
sessions covered similar
issues but provided more indepth drug counseling)
medical management
Physicians met with patients
monthly (20 minutes; sessions
paralleled that of the standard
sessions, with the addition of
an assessment of employment,
legal, family or social, medical,
and psychiatric problems
related to addiction)
The nurses, a physician, and a
psychologist met weekly to
review the counseling

F-7

Setting/ Provider
Type/ Staffing

Findings

The efficacy of brief
weekly counseling and
once-weekly medication
dispensing did not differ
significantly from that of
extended weekly
counseling and
thrice-weekly dispensing

Model name
Author, year

Comparators

Duration of N
Followup

Fiellin, 20138

Physician
24 weeks
management (15-20
minutes weekly for the
first 2 weeks, every 2
weeks for the next 4
weeks, and then
monthly) with
buprenorphinenaloxone or physician
management with
buprenorphinenaloxone plus CBT (up
to 12 50-minute weekly
sessions during the
first 12 weeks of
treatment)

141

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

USA; 74% male;
90% white; mean
age 34 years;
mean time opioid
dependent 8
years; 35%
prescription drug
use; 32% current
injection drug
use; 45% prior
attempted
detoxification;
59% prior
substance abuse
treatment; mean
1.3 days of use of
cocaine in
previous 30 days

Physician management (15-20
minutes; sessions occurred
weekly for the first 2 weeks,
every 2 weeks for the next 4
weeks, and then monthly). The
physician followed a structured
note that reviewed the patient’s
recent drug use; provided brief
advice on how to achieve or
maintain abstinence;
supported efforts to reduce
drug use or remain abstinent;
reviewed medical and
psychiatric symptoms;
assessed social, work, and
legal function; discussed
weekly urine toxicology results;
and reviewed attendance at
self-help groups.CBT was
provided using a CBT manual
adapted for cocaine
dependence. Fidelity
measures were taken and
supervision provided. Patients
were offered up to 12 50minute weekly sessions during
the first 12 weeks of treatment.
The main components of
counseling focused on
performing a functional
analysis of behavior, promoting
behavioral activation,
identifying and coping with
drug cravings, enhancing drugrefusal skills, enhancing
decision-making about highrisk situations, and improving
problem-solving skills.

Internal medicine
physicians with
experience providing
buprenorphine, trained
masters and doctorallevel clinicians
Primary care clinic

F-8

Types of Outcomes and
Harms Examined and
How They Were
Measured
Frequency of illicit opioid
use: self-report
Maximum number
ofconsecutive weeks of
abstinence from illicit
opioids: urine toxicology
and self-report
Also, the proportion of
patients remaining in the
study (the percentage of
patients who did not meet
the criteria for protective
transfer, did not miss
medication for 7 days, or
did not miss 3 physician
management sessions),
the number of days of the
study that were completed,
and self-reported
abstinence from cocaine
use (verifiedby urinalysis)

Findings

The effectiveness of
physician management
did not differ significantly
from that of physician
management plus CBT.

Model name
Author, year

Comparators

Galanter, 20049

Buprenorphine plus
18 weeks
medication
management (2
individual sessions per
week) vs.
buprenorphine plus
network therapy (1
individual and 1 group
counseling session per
week)

Moore, 201210

Duration of N
Followup

Buprenorphine and
12 weeks
physician management
(15 minute sessions
weekly) vs.
buprenorphine and
physician management
plus CBT (45 minute
sessions weekly,
depending on therapist
availability)

Population
Characteristics

66

55

Specifics of Model
Components/
Implementation

Types of Outcomes and
Harms Examined and
How They Were
Measured
USA; 76% male; Patients underwent induction Office-based; Therapies Illicit drug use: urine
59% white, 24% on buprenorphine/naloxone,
provided by psychiatry toxicologies, percentage of
Hispanic, 12%
maintenance phase, and taper resident physicians
negative screens (goal of
Black, 5%
off over 15 weeks, doses given
adherence to abstinence
Asian/other;
daily aside for weekend takeexpectation) and whether
mean age 36
home dosing
or not last 3 scheduled
years; mean 12
urines in study were
years of heroin
Network therapy had one
negative (goal of opiateuse; 33% had
group and one individual
free state by end of
treatment)
injection drug use session per week;
in past 30 days; Network therapy trains network
73% had history members to provide supportive
of treatment for
environment for patient's
heroin addiction, adherence to avoidance of
30% had history illicit drug use, joint sessions
of methadone
with support network members
maintenance
as well as individual sessions
treatment
organized;
Medication management had
two individual sessions per
week; medication management
focused on medication
response and adherence
monitoring and the
establishment of therapeutic
relationship
France; 74%
Physician management
male; mean age included weekly buprenorphine
39 years; 72%
dispensing, 15 minutes per
white; mean
session Other arm included
opioid
physician management and
dependence 9
thrice weekly directly observed
years; 45%
buprenorphine therapy plus
prescription drug weekly CBT, 45 minutes per
use; 16% history session, based on therapist
of IV drug use;
availability
41% prior
attempted
detoxification

F-9

Setting/ Provider
Type/ Staffing

Adult primary care
center of an urban
teaching hospital;
Physician management
provided by primary
care internal medicine
physician with
experience in officebased buprenorphine
treatment.
CBT provided by
trained therapists (2
master's level and 3
doctoral-level) with at
least 3 years of
experience.
Induction performed by
trained nursing staff.

Drug use: urine toxicology
and self-report
Treatment completion:
continued participation
through the 14th week;
Treatment retention:
number of weeks;
Patient satisfaction:
Primary Care
Buprenorphine Satisfaction
Scale

Findings

Network therapy led to
significantly more
negative urine
toxicologies and more
network therapy than
medication management
patients had positive
outcome relative to
secondary heroin use by
the end of treatment

Analyses adjusting for
baseline characteristics
showed no significant
differences between
groups on retention or
drug use based on selfreport or urines. Patient
satisfaction was high
across conditions,
indicating acceptability of
CBT counseling with
observed medication. The
number of CBT sessions
attended was significantly
associated with improved
outcome, and session
attendance was
associated with a greater
abstinence the following
week.

Model name
Author, year

Comparators

Duration of N
Followup

Sullivan, 20066
(also a model of
care)

Buprenorphine/naloxon 12 weeks
e and physician
management (brief,
biweekly) vs.
buprenorphine/naloxon
e and physician
management plus
once-weekly drug
counseling and
adherence
management

Population
Characteristics

16

USA; 94% male;
31% white, 44%
Black, 25%
Hispanic; mean
age 47 years;
mean 17 years
opioid
dependence;
56% with injection
drug use; 29%
reported one or
more days of
alcohol use in
past 30 days;
36% reported one
or more days of
cocaine use in
past 30 days;
100% HIV
positive; mean 13
years since HIV
diagnosis; 63%
currently on ART;
81% HCV
positive

Specifics of Model
Components/
Implementation

Types of Outcomes and
Harms Examined and
How They Were
Measured
Buprenorphine/naloxone
HIV clinics;
Treatment retention
stabilization over 2-weeks with Buprenorphine and
Illicit drug use: urine
clinic visits 3 times per week
physician management toxicology and self-report
and 1 and 2-day take home
provided by physician
Laboratory parameters:
doses then 10-week
specialized in addiction CD4 count, viral load, and
maintenance period with once medicine and
liver function tests
weekly clinic visits and 6 take experienced in HIV
Adherence to MAT and
home doses then offered 2care; drug counseling
ART: Medication Event
week taper or extension
and adherence
Monitoring System (caps
phase; all patients received
management provided that record the date and
brief, bi-weekly, manual-guided by trained nursing staff time the pill bottle was
(issues reviewed with
opened)
physician management that
supervising physician
HIV transmission risk
focused on symptoms, drug
and clinical
behaviors: HIV/AIDS Risk
use, and progress; half of
psychologist)
Inventory
patients received physician
Health status: SF-36
management plus once-weekly
Patient satisfaction: 5-point
drug counseling and
adherence management
Likert scale questionnaire
focused on addiction-specific
topics like triggers,
relationships, and craving and
strategies to increased
adherence to antiretroviral
treatment

F-10

Setting/ Provider
Type/ Staffing

Findings

There was no difference
in treatment retention or
illicit drug use by
counseling group; Overall,
the proportion of opioidpositive weekly urine
screens decreased
substantially over trial;
CD4 counts remained
stable; viral load declined
significantly;
demonstrated feasibility of
integrating buprenorphine
into HIV clinical care for
treatment of opioid
dependence

Model name
Author, year

Comparators

Duration of N
Followup

Tetrault, 201211

Physician
management (brief,
once every 2 weeks)
vs. physician
management plus
enhanced medical
management (45
minutes weekly;
focused on drug
counseling and
adherence to antiretroviral treatment)

12 weeks

Population
Characteristics

47

USA; 39% male;
29% white; mean
age 47 years;
mean 4 days of
alcohol use in
past 30 days;
mean 5 days of
cocaine use in
past 30 days;
mean 17 years of
opioid
dependence;
87% with primary
heroin use; 49%
with injection drug
use; mean 12
years duration of
HIV diagnosis;
61% receiving
ART, 26% HCV
positive

Specifics of Model
Components/
Implementation

Types of Outcomes and
Harms Examined and
How They Were
Measured
Physician management group HIV clinic; Physicians
Illicit drug use: percentage
had physician visit once every for medication and
of opioid-negative urine
2 weeks where they took
physician management; specimens, drug urine
medication under observation nurses delivered
screen; and self-report
and were given a supply to
enhanced medical
Abstinence: self-report
take-home; physician
management
Study completion: not
management was brief,
meeting criteria for
manual-guided, medically
protective transfer (3
focused counseling
consecutive positive urine
intervention that focused on
tests after buprenorphine
drug use, symptoms, side
dose increased), continued
effects. Enhanced medical
research visits and
management group had clinic
medication dispensing
weekly, took medication under
through week 12
observation, and given supply
MAT and ART adherence:
to take home; enhanced
computerized bottle caps
medical management was a
HIV clinical data: CD-4 and
manual-guided counseling
viral load HIV risk
intervention lasting 45 minutes
behaviors: AIDS Risk
focused on drug counseling
InventoryImpact of opioid
and adherence to ART
treatment and counseling
into HIV setting:
buprenorphine/naloxone
dose, number of sessions
attended, length of visits,
number of sessions missed

F-11

Setting/ Provider
Type/ Staffing

Findings

At end of trial, no
difference between
groups in percentage of
opioid negative urines,
maximum duration of
continuous abstinence, or
retention; the percentage
of subjects with detectable
viral loads decreased from
baseline across both
groups similarly; overall,
providing extended
counseling in this setting
is feasible but does not
provide detectable
improvement in outcomes

Model name
Author, year

Comparators

Duration of N
Followup

Weiss, 201112
Prescription
Opioid Addiction
Treatment Study
(POATS)

Phase 1: Standard
medication
management (after
initial session,15-20
minute s weekly, then
biweekly sessions with
a physician) with
buprenorphine/
naloxone vs. standard
medication
management with
buprenorphine/
naloxone plus opioid
dependence
counseling (45-60
minute sessions with a
counselor, twice
weekly then biweekly)
Phase 2 (extended
treatment for those
who relapsed):
Standard medication
management (2 visits
first week, then
weekly) with
buprenorphine/
naloxone vs. standard
medication
management with
buprenorphine/
naloxone plus opioid
dependence
counseling (twice
weekly then biweekly)

Phase 1: 12
weeks
Phase 2 (for
patients with
unsuccessful
outcomes):
24 weeks

653

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

USA; 60% male;
91% white; mean
age 33 years;
27% alcohol
dependence
during lifetime;
18% cocaine
dependence
during lifetime; 5
mean years of
opioid use; 23%
used heroin ever;
32% previous
treatment for
OUD; 42%
current chronic
pain

Physicians provided manualbased, standard medical
management. During the initial
sessions (45-60 minutes in
phase 1 and 30-60 minutes in
phase 2), the physician
reviewed the patient’s medical,
psychiatric, and substance use
problems; recommended
abstinence; and referred the
patient to self-help groups. In
subsequent visits (15-20
minutes), the physician
assessed substance use,
craving, and buprenorphinenaloxone response;
recommended abstinence and
self-help participation; and
prescribed buprenorphinenaloxone.The comparison
group received standard
medical management and
manual-based opioid
dependence counseling (45-60
minute sessions). Opioid
dependence counseling was
based on drug counseling
manuals with demonstrated
efficacy, modified for this study
of prescription opioid
dependence treatment with
buprenorphine. Counselors
educated patients about
addiction and recovery,
recommended self-help
groups, and emphasized
lifestyle change. Using a skillsbased format with interactive
exercises and take-home
assignments, opioid
dependence counseling
covered a wider range of
relapse prevention issues in
greater depth than did
standard medication
management, including coping
with high-risk situations,
managing emotions, and
dealing with relationships.

Physicians certified to
prescribe
buprenorphine, trained
substance abuse or
mental health
professionals10
study/treatment sites
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Types of Outcomes and
Harms Examined and
How They Were
Measured
Opioid use: urine
toxicology and selfreportPhase 1
successfuloutcome:
completing week 12 with
opioid use on no more than
4 days in a month,
absence of 2 consecutive
opioid-positive urine test
results, no additional
substance use disorder
treatment, and no more
than 1 missing urine
sample during the 12
weeks
Phase 2 successful
outcome:abstaining from
opioids during week 12
and during at least 2 of the
previous 3 weeks

Findings

During phase 1, only 6.6%
of patients had successful
outcomes, with no
difference between
standard medical
management or standard
medical management plus
opioid dependence
counseling. During phase
2, 49% attained
successful outcomes, with
no difference between
groups. Success rates 8
weeks after completing
the buprenorphinenaloxone taper (phase 2,
week 24) dropped to
8.6%, again with no
difference between
groups.

Model name
Author, year

Comparators

Duration of N
Followup

Weiss, 201513

See above

9 month
treatment;
42 month
followup

Prescription
Opioid Addiction
Treatment Study
(POATS)

375

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

USA; 56% male;
90% white; mean
age 33 years old;
3.7% with alcohol
dependence in
past year; 5.9%
with cannabis
dependence in
past year; 3.2%
with cocaine
dependence in
past year; 3.5%
with other
stimulant
dependence in
past year; 4.8%
with sedativehypnotic
dependence in
past year; mean 5
years of opioid
use; 22% had
ever used heroin;
78% used opioids
through route
other than
sublingually/
swallowed

Standard medication
management included weekly
visits with physician, combining
medication administration with
medication-focused
counseling; phase 1 was 4week medication taper; phase
2 for those who relapsed
included medication for 12
weeks then 4-week taper
Opioid dependence counseling
focused on relapse prevention,
skill-building, and lifestyle
change opioid dependence
counseling twice weekly for six
weeks then once weekly for 6
weeks

Office-based; primary
care; Physicians for
medication
management and
counseling
Opioid dependence
counseling providers
not described but
appear to be
physicians; research
assistants conducted
followup phone
interviews
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Types of Outcomes and
Harms Examined and
How They Were
Measured
Followup measures: phone
calls at 18, 30, and 42
months and included the
Composite International
Diagnostic Interview for
opioid diagnosis, the ASI
for substance use severity,
four items from SF-36 for
general health and pain,
the Fagerstrom Test for
Nicotine Dependence for
smoking dependence
severity, subset from the
Pain and Opiate Analgesic
Use History

Findings

Few participants had
successful opioid
outcomes in phase 1;
almost half had successful
opioid treatment in phase
2; addition of opioid
dependence counseling to
medication did not
improve outcomes; one
third of those in followup
abstained and were not
on agonist medication,
one third were abstinent
on agonist therapy and
another third were using
opioids (followup
outcomes not described
by group)

Model name
Author, year

Comparators

Duration of N
Followup

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

Types of Outcomes and
Harms Examined and
How They Were
Measured

Findings

France; 84%
male; median age
32 years (IQR:
27-38); 27% used
cocaine; 72%
used street
opioids; 20%
used
psychotropic
drugs; 15% drug
injection users;
64% drug
snorting users;
18% were daily
cannabis users;
33% had
hazardous
alcohol
consumption;
12% history of
drug overdose;
17% history of
suicide
attempt,;2% HIVpositive, 19%
HCV-positive;
49% history of
drug injection

Evaluation of implementation
strategy of 14-day supervised
methadone induction, with
starting dose of 30-40 mg, with
10 mg increases every 2-4
days, until dose stabilization.
Took into account those who
switched from buprenorphine
to methadone at enrollment.

Physicians in 10 sites;
specialty care and
primary care physicians
with field experience in
care for opioid
dependence and/or
training in care for drug
dependence

Abstinence from streetopioids at 12 months using
a validated question
administered during phone
interviews, engagement in
treatment computed as the
proportion of patients who
actually started methadone
and remained in the trial
until the stabilization of
dosages, retention in
methadone maintenance
treatment only for patients
who actually started
methadone treatment
recorded as the time
between the first day of
methadone induction and
the last known date that
the patient was still
receiving treatment, and
patient satisfaction on a 5point Likert scale that was
dichotomized as very
satisfied vs. other.
Pharmacies and
physicians recorded
overdoses, signs of
intoxication, and lost-tofollowup. A list of 50
health-related symptoms
was included in a
questionnaire that helped
document self-reported
symptoms.

Under appropriate
conditions, methadone
induction in primary care
is feasible and acceptable
to both physicians and
patients. It is as effective
as induction in specialized
care in reducing streetopioid use and ensuring
engagement and retention
in treatment for opioid
dependence.

Pharmacological
Therapies
Carrieri, 201414

Induction of
12 months
methadone in primary
care vs. specialty care

221
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Model name
Author, year

Comparators

Duration of N
Followup

(Carrieri 2014
pilot study)
Roux, 201215

See above

2 weeks
induction
12 months
followup for
outcomes

Population
Characteristics

195

Specifics of Model
Components/
Implementation

Types of Outcomes and Findings
Harms Examined and
How They Were
Measured
Study conducted Induction model included: 1)
Primary care and
Abstinence from streetNR
in France, no
study-specific pretraining for
medical center; Clinic
opioids at 12 months using
other information primary care physicians; 2) a visits and phone
a validated question,
provided
shared care model, based on interviews; Trained
retention in treatment,
the patient primary
primary care and
occurrence of overdoses,
care physicians-Center for
Center for Drug Abuse prevalence of other HCV
Substance Abuse Prevention Prevention Association risk transmission practices,
Association -pharmacist
physicians
depressive symptoms
network; 3) the exclusion of
using CES-D, suicidal risk
patients with triple
using Beck Hopelessness
codependence on
Scale, impulsivity using the
opioids/benzodiazepines/alcoh
Barratt Impulsiveness
ol, as screened by MiniScale, sensation seeking
International Neuropsychiatric
using the Brief Sensation
Interview; 4) the daily
Seeking Scale, tobacco
supervision at the local
dependence using the
pharmacy during the initiation
Fagerstrom test, alcohol
phase for patients starting
consumption using the
methadone in primary care; 5)
AUDIT questionnaire, pain
patient accountability for
assessment using the Brief
treatment intake
Pain Inventory, adherence
and appropriate storage
to methadone prescription,
patient-health care
provider relationship,
opioid withdrawal, quality
of life using SF-12, adult
ADHD Self-Report Scale 6
item version, urinary drug
screening, and sociodemographic information
on history of incarceration
and contact with
associations.
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Setting/ Provider
Type/ Staffing

Model name
Author, year

Comparators

Duration of N
Followup

Fiellin, 200116

Primary care-based
6 months
methadone (weekly
physician sessions and
monthly counseling
session) vs. narcotic
treatment programbased methadone (1 to
3 sessions per week
dose, weekly group
counseling, and
monthly individual
counseling)

Population
Characteristics

46

Specifics of Model
Components/
Implementation

Types of Outcomes and
Harms Examined and
How They Were
Measured
USA; 65% male; Office-based group had weekly Offices of general
Illicit drug use: self-report,
78% white; mean physician contact for
medicine internists who urine and hair toxicology
age 42 years;
medication dosing and 6 take- provided all officePatient and clinician
17% HIV-positive; home doses plus monthly
based care (4/6 were
satisfaction: 5-point Likert
counseling session
certified in Addiction
scale questionnaire
91% with prior
Medicine);
Functional status: SF-36,
detoxification
ASI and modified
attempt; 72% with Narcotic treatment program
Treatment center was Treatment Services
history of IV drug group had 1 to 3 treatment
center visits per week for
site of narcotic
Review; Depression:
use
methadone dose and taketreatment program;
Center for Epidemiologic
home dosing plus weekly
Physicians, counselors, Studies Depression Scale
group and monthly individual social workers, and
counseling
employment services
provided narcotic
Note: patients who had a
treatment program
positive random urine sample
or urine that did not show
methadone and a repeat urine
sample that was positive and
did not show methadone were
considered clinically unstable
and care was escalated
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Setting/ Provider
Type/ Staffing

Findings

There was no significant
between-group difference
on illicit drug use or
patients with clinical
instability; Significantly
more office-based
patients thought that
quality of care was
excellent; There were no
group differences in
functional status or use of
health, legal, or social
services; Overall, results
supported feasibility and
efficacy of transferring
stable opioid-dependent
patients to primary care
for methadone
maintenance

Model name
Author, year

Comparators

Duration of N
Followup

Population
Characteristics

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

Fudala, 200317

Daily
buprenorphine/naloxon
e vs. buprenorphine
vs. placebo
All participants
received HIV
counseling and up to 1
hour of individualized
counseling per week;
emergency counseling
and referrals provided

4 weeks for
efficacy; 4852 weeks for
safety

Efficacy sample:
USA; 65% male;
mean age 38
years; 61% white,
28% black, 7.1%
Hispanic, 1.2%
Native American,
2.2%
Asian/Pacific
Islander; median
84 month (range:
3 to 468) duration
of heroin abuse;
51% with prior
enrollment in
methadone or
LAAM program
Safety sample:
USA; 69% male;
mean age 39
years; 50% white,
30% black, 17%
Hispanic, 0.8%
native American,
1.9%
Asian/Pacific
Islander; median
120 months
(range: 3 to 468)
duration of heroin
abuse; 50% with
prior enrollment in
methadone or
LAAM program

Provided daily MAT or placebo
administered on site with takehome dosing for
weekends/holidays; during
open-label phase, up to 10-day
supply of medication provided;
all participants received HIV
counseling and up to 1 hour of
individualized counseling per
week; emergency counseling
and referrals provided

Physician's office in a
clinical research
program distinct from
methadone clinic
(provider type not
described)

323 for
efficacy;
472 for
safety
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Types of Outcomes and
Harms Examined and
How They Were
Measured
Opiate use: percentage of
opiate-negative urine
samples
Opiate craving: self report
Overall status: per
participant and per
clinicianIllicit drug use
other than opiates:
percentage of negative
urine drug screens
Subject retentionRates of
adverse medical events
Electrocardiography and
laboratory findings

Findings

Efficacy study terminated
early due to greater
efficacy of
buprenorphine/naloxone
and buprenorphine vs.
placebo; Proportion of
opiate-negative urine
samples significantly less
among both MAT groups
vs. placebo; MAT groups
reported significantly less
opiate craving than
placebo; Rates of adverse
events similar in activetreatment and placebo
groups; findings from
open-label followup
indicated combined
treatment was safe and
well tolerated

Model name
Author, year

Comparators

Duration of N
Followup

Population
Characteristics

King, 200618

Routine care
12 months
(methadone
dispensing window for
weekly doses and
monthly counseling for
20 minutes) vs.
methadone
maintenance clinic
(monthly observed
dose, take home
supply, monthly 20
minute counseling
session with medical
provider) vs. primary
care based-methadone
(monthly observed
dose, take home
supply, monthly 20
minute counseling
session with office
physician)

92

USA; 62% male;
72% white; mean
age 44 years; no
patient included
had submitted
positive breath
intoximeter
readings in past
year; mean 14
years of
methadone
treatment
received over
lifetime

Lintzeris, 200419

Methadone vs.
12 months
buprenorphine
administered under
naturalistic conditions
by 18 communitybased and 1 specialistbased sites by general
practitioners and
community
pharmacists
(Buprenorphine
Implementation trial
[BIT])

139

Australia; 58%
male; mean age
30 years; mean
age of first heroin
use 21 years;
mean duration
lifetime
methadone
treatment 27
months; 0-32%
reported no
heroin use in past
month

Specifics of Model
Components/
Implementation

Setting/ Provider
Type/ Staffing

Types of Outcomes and
Harms Examined and
How They Were
Measured
Routine care group received 1- Community primary
Illicit substance use: urine
2 doses of methadone per
health care center and specimens
week at dispensing window
one addiction treatment Medication monitoring:
and 5-6 take-home doses with center as sites of office- random medication recalls
once-monthly appointments
based methadone
Addiction-related issues in
with the clinic counselorClinic- medical maintenance; past 30 days: ASI
based methadone medical
Physician provided
Patient Satisfaction: Client
maintenance received one
medication and
Satisfaction Questionnaire
dose of methadone observed counseling
Quality of therapeutic
by nurse or physician and 27 Clinic-based
relationship: Helping
days of take-home methadone methadone medical
Alliance Questionnaire for
every 4 weeks and monthly
Patients
maintenance at two
appointments with clinic
Other measures: Postcommunity-based
counselor Office-based
study opinion survey
methadone
methadone medical
maintenance treatment Monthly hours in treatment:
maintenance received one
programs; nurse or
patient estimates of time
dose of methadone observed physician provided
spent engaged in
by physician and 27 days of
medication and
treatment-based activities
take-home doses every 4
counselor provided
Engagement in
weeks from physician's office counseling
employment, family/social,
and had monthly counseling
and personal activities:
session with physician Note: if
patient estimates
found to have positive urine or
failed medication recall,
participant was stepped-up in
care
Methadone treatment
First intake of study
Retention in treatment:
consistent with state guidelines conducted in specialist pharmacy records
with supervised dispensing at clinic; second intake of Heroin use: Self report
pharmacies and one takestudy conducted in
using Opiate Treatment
away dose per week for stable community setting with Index
patients; dose, frequency or
primary care clinicians
review, counseling was tailored and pharmacists
per patients; Buprenorphine
treatment consisted of flexible
dosing and at least monthly
review, optional
psychotherapy; daily
dispensing at induction with
alternate-day or 3-day dosing
once stable

Findings

Generally low rates of
drug use or failed
medication recall with
good study retention; No
between-group
differences on ASI scores;
Treatment satisfaction
was high in all groups and
patients in all groups rated
strong quality of
therapeutic alliance;
methadone medical
maintenance patients in
both office and clinicbased care initiated more
new employment or
social/family activities
than routine care; most
methadone medical
maintenance patients
reported a preference for
office-based care
compared with clinicbased

Among methadone
stabilized patients, mean
retention time was similar
between groups; among
heroin users, there was a
trend towards improved
retention among those
taking methadone
compared with those on
buprenorphine, though
this was not statistically
significant; There were
significant reductions in
heroin use in all groups
over time and a trend
toward lower heroin use
among heroin users on
buprenorphine

ADHD = attention deficit hyperactivity disorder; ART = anti-retroviral treatment; ASI = addiction severity index; AUDIT = Alcohol Use Disorders Identification Test; BFC = behavioral family
counseling; CBT = cognitive behavioral therapy; CD4 = cluster of differentiation 4 glycoprotein; CES-D = Center for Epidemiological Studies Depression; ED = emergency department; EMM =
enhanced medical management; HCV = hepatitis C virus; HIV = human immunodeficiency virus; IBT = individual based treatment; IV = intravenous; IQR = interquartile range; LAMM = levoalpha-acetylmethadol; MAT = medication assisted treatment; NR = not reported; OUD= opioid use disorder; PM = physician management; RNA = ribonucleic acid; SD = standard deviation; SF12 = Medical Outcomes Study Short-Form 12; SF-36 = Medical Outcomes Study Short-Form 36; USA = United States of America; vs. = versus
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Appendix G. Details of Cochrane Systematic Reviews for Guiding Question 3
Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

Types of
Studies
Included

Amato,
201120

To evaluate
the
effectiveness
of any
psychological
plus any
agonist
maintenance
treatment vs.
standard
treatment for
opiate
dependence

Cochrane
libraries,
PUBMED,
EMBASE,
CINAHL,
PsycINFO
(through
June 2011)

35

OUD due to
opiates (not
specified);
setting not
described
(appears mostly
specialist
centers); USA,
Germany,
Malaysia, China,
Scotland

Any psychosocial RCTs,
intervention plus CCTs
any agonist vs.
any agonist
alone; medical
interventions
were methadone,
buprenorphine,
LAAM; models of
care not
described

Ferri,
201321

To evaluate
efficacy of
slow-release
oral morphine
for treatment
of opioid
dependence

Cochrane
libraries,
MEDLINE,
EMBASE
(through
April 2013)

3

OUD due to
heroin; Setting
not described;
Australia and
Austria

Slow-release oral
morphine vs.
other MAT
medications;
models of care
not described

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane
(Higgins,
2011)

RCTs,
Cochrane
quasi(Higgins,
randomize 2011)
d (one
study only
provided
conference
abstract)

G-1

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE;
metaanalysis
done

GRADE;
no metaanalysis

Total
Findings
Numbers
of
Patients

4319

195

Comparing any
psychosocial intervention
plus maintenance
pharmacological
treatment to standard
maintenance treatment,
shows no significant
advantage of adding
psychosocial interventions
for retention in treatment
and at followup,
abstinence from opiates
during treatment or at
followup, compliance,
psychiatric symptoms,
and depression. Also,
there was no significant
difference in outcomes
comparing psychosocial
approaches. Of note,
standard pharmacological
treatment generally offers
counseling services.
Limited evidence that
sustained-release oral
morphine is at least
similar to other MAT
medications for retention
and other clinical
outcomes

Adverse
Events

Limitations

Not reported Focused on
effectiveness of
psychotherapy
interventions in
addition to
standard
interventions;
setting not
described
(appears mostly
specialist
centers); 31
studies in USA

Limited
evidence of
no major
differences
in adverse
events

Focused on
effectiveness of
medications;
trials with no
description of
setting; no
studies in USA

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Gowing,
201122

To assess the
effect of oral
substitution
treatment for
opioid
dependent
injecting drug
users on risk
behaviors and
rates of HIV

Cochrane
libraries,
MEDLINE,
EMBASE,
psycINFO
(through
May 2011)

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

38

Types of
Studies
Included

Methods
for Rating
Methodological
Quality of
Primary
Studies
OUD due to
Buprenorphine,
RCTs,
Cochrane
heroin; majority methadone, or
observation (Higgins,
injecting drug
LAAM for
al
2008)
users or with
substitution
prospective
recent history
therapy (alone or studies,
(last 3 months); vs. others);
crossusers of other
models of care
sectional
injectable drugs not described
studies
also included;
mostly specialist
treatment
centers; USA,
UK, Australia,
Italy, Germany,
Canada,
Malaysia,
Ukraine with one
study in multiple
countries

G-2

Methods
for
Synthesizing
Results of
Primary
Studies
Unclear for
quality; No
metaanalysis

Total
Findings
Numbers
of
Patients

12400

Adverse
Events

Oral substitution treatment Not reported
with methadone or
buprenorphine is
associated with significant
reductions in illicit opioid
use, injecting use, and
sharing of injecting
equipment; also led to
fewer drug users reporting
multiple sex partners or
exchanges of sex for
money or drugs but no
change in condom use;
reduced drug risk
behaviors led to reduced
HIV; one study partially
done in primary care
showed significant
reductions in proportion
injecting, sharing injecting
equipment, and having
unprotected sex in those
on methadone treatment.

Limitations

Focused on
effectiveness of
medications on
HIV and
behaviors; 2
studies
included
primary care
settings; 26
studies in USA

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

Lobmaier,
200823

To evaluate
the
effectiveness
of sustainedrelease
naltrexone for
opioid
dependence
and its
adverse
effects in
different
populations

Cochrane
1 for
OUD not
libraries,
effective- specified;
MEDLINE,
ness; 10 effectiveness
EMBASE,
for safety study in
CINAHL,
in OUD outpatient
LILACS,
setting;
PsycINFO,
Australia,
ISI Web of
Germany, USA,
Science,
Norway, Spain,
clinicaltrials.
UK
gov (through
November
2007)

Three depot and
two implant
formulations of
naltrexone (10 of
17 depot studies
used sustained
release form) vs.
placebo, different
naltrexone doses,
oral naltrexone,
or methadone; in
addition to
medication, all
patients offered
relapse
prevention
therapy

Types of
Studies
Included

Methods
for Rating
Methodological
Quality of
Primary
Studies
RCTs for
Cochrane
effectivene (Higgins,
ss;
2006)
prospective
controlled
and
uncontrolle
d trials,
caseseries, and
recordlinkage for
safety
evaluation

G-3

Methods
for
Synthesizing
Results of
Primary
Studies
Unclear for
quality;
metaanalysis
done for
safety

Total
Findings
Numbers
of
Patients

Adverse
Events

Limitations

60 for
effectiven
ess;
mean 168
(range: 5
to 894) for
safety in
OUD

Limited data
showing
side effects
were
significantly
more
frequent in
naltrexone
depot
groups vs.
placebo
(mostly siterelated);
among
OUD, no
significant
group
differences
in adverse
events; most
studies
lacked
systematic
assessment
of side
effects and
adverse
events were
rare

Focused on
effectiveness
and adverse
events of
medications;
effectiveness
study in
outpatient
setting (no
further details);
effectiveness
study and most
safety studies
done in USA

One study found highdose naltrexone depot
injections significantly
increased days in
treatment vs. placebo and
vs. low-dose with no
group differences on
patients retained in
treatment;

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Mattick,
200924

To evaluate
the effects of
methadone
maintenance
treatment
compared
with other
treatment that
did not
involve opioid
replacement
therapy for
opioid
dependence

Cochrane
libraries,
EMBASE,
PUBMED,
CINAHL,
Current
Contents,
PsycLIT,
CORK,
Alcohol and
Drug Council
of Australia,
Australian
Drug
Foundation,
Centre for
Education
and
Information
on Drugs
and Alcohol,
Australian
Bibliographic
Network,
Library of
Congress
(through
December
2008)

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

11

OUD due to
opioids (not
specified); most
studies done in
specialist
medical or
research
facilities (3 in
prison setting);
USA, Australia,
Hong Kong,
Thailand,
Sweden

Types of
Studies
Included

Methadone
RCTs
maintenance vs.
placebo or other
nonpharmacologi
cal therapy (waitlist control, drugfree rehabilitation,
detoxification);
models of care
not described
(some studies
included
counseling in the
intervention but
this was not
described)

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane focus on
randomizati
on

G-4

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE;
metaanalysis
done

Total
Findings
Numbers
of
Patients

1969

Adverse
Events

Methadone was
Not reported
significantly more effective
than nonpharmacological
approaches in treatment
retention and suppression
of heroin use but not
different in criminal activity
or mortality

Limitations

Focused on
effectiveness of
medication; no
studies appear
to be have
been done in
primary care; 6
studies in USA

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Mattick,
201425

To evaluate
buprenorphin
e
maintenance
compared to
placebo and
to methadone
maintenance
in the
management
of opioid
dependence,
including its
ability to
retain people
in treatment,
suppress illicit
drug use,
reduce
criminal
activity, and
mortality

Cochrane
libraries,
MEDLINE,
EMBASE,
Current
Contents,
PsycLIT,
CORK,
Alcohol and
Drug Council
of Australia,
Australian
Drug
Foundation,
Centre for
Education
and
Information
on Drugs
and Alcohol,
Library of
Congress
(through
January
2013)

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

31

OUD due to
heroin or other
opioids; setting
not described;
North America,
Europe, Asia,
Middle East,
Australia

Buprenorphine
maintenance vs.
placebo or
methadone;
models of care
not described

Types of
Studies
Included

RCTs

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane
(Higgins,
2011)

G-5

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE;
metaanalysis
done

Total
Findings
Numbers
of
Patients

5430

Buprenorphine was
superior to placebo in
participant retention at all
doses; only high-dose
buprenorphine (not low- or
moderate-dose) was more
effective than placebo in
suppressing illicit opioid
use; flexible dosed
buprenorphine was less
effective than methadone
in participant retention
with no group differences
in suppression of opioid
use; low-dose methadone
was more likely to retain
participants and limit
opioid use than low-dose
buprenorphine but high
and medium-dose
methadone were not more
effective than high and
medium-dose
buprenorphine for
participant retention and
illicit opioid use

Adverse
Events

Limitations

Limited
evidence of
no
significant
differences
between
methadone
and
buprenorphi
ne (one
result of
more
sedation
among
methadone
users)

Focused on
effectiveness of
medications;
setting not
described; 15
studies from
North America

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Minozzi,
200926

Among
adolescents
(13-18 years
old), to
assess the
effectiveness
of any
maintenance
treatment
alone or in
combination
with
psychological
intervention
compared to
no
intervention,
other pharmacological or
psychosocial
intervention
on retaining
adolescents
in treatment,
reducing
substance
use, and
reducing
health and
social status

Cochrane
libraries,
MEDLINE,
EMBASE,
CINHAL
(through
August
2008)

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

2

OUD due to
Methadone
heroin;
maintenance vs.
outpatient; USA LAAM;
buprenorphinenaloxone
maintenance vs.
buprenorphine
detoxification;
models of care
not described

Types of
Studies
Included

RCTs and
controlled
clinical
trials

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane
(Higgins,
2008)

G-6

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE;
no metaanalysis

Total
Findings
Numbers
of
Patients

187

Limited evidence that
maintenance treatment
was superior in patient
retention but not in
reducing illicit opioid use;
Opioid use at 1 year
followup was significantly
lower in the maintenance
group and more patients
in this group were enrolled
in other addiction
treatment at followup

Adverse
Events

Limitations

Limited
evidence of
no serious
side effects
or
withdrawals
attributable
to buprenorphinenaloxone

Focused on
effectiveness of
medications;
outpatient
setting (unclear
if primary care);
all trials done in
USA

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Minozzi,
201127

To evaluate
the effects of
naltrexone
maintenance
treatment vs.
other
treatments/
placebo in
preventing
relapse in
opioid addicts
after
detoxification

Cochrane
libraries,
PubMed,
CINAHL
(through
June 2010)

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

13

OUD due to
heroin alone or
multiple drugs;
outpatient only;
USA, Israel,
Russia, Italy,
Spain, China,
Malaysia,
Germany

Types of
Studies
Included

Oral naltrexone
RCTs
alone or in
combination with
psychosocial
treatments vs.
placebo, no
intervention, other
pharmacological
treatments, or
psychosocial
treatments;
models of care
not described

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane
(Higgins,
2008)

G-7

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE
(ratings not
shown);
metaanalysis

Total
Findings
Numbers
of
Patients

1158

Oral naltrexone did not
perform better than
treatment with placebo or
no agent with respect to
abstinence and relapse,
though naltrexone was
favored for number of
people reincarcerated.
Naltrexone was not
superior to
benzodiazepines and
buprenorphine for
retention, abstinence, and
side effects, though
numbers retained in
studies were generally
low. In single study of
naltrexone vs.
psychotherapy, there was
no statistically significant
difference for abstinence
and reincarceration.
Overall, studies
inadequate to evaluate
oral naltrexone treatment
for opioid dependence.

Adverse
Events

Limitations

Limited
evidence of
no
significant
differences
in adverse
events

Focused on
effectiveness of
medications
/interventions;
includes
psychotherapy
as an
intervention;
outpatient trials
(unclear if
primary care); 4
trials in USA

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Minozzi,
201328

Among
pregnant
women, to
assess the
effectiveness
of any
maintenance
treatment
alone or in
combination
with
psychosocial
intervention
compared to
no
intervention,
other
pharmacologi
cal or
psychosocial
interventions
for child
health status,
neonatal
mortality,
treatment
retention, and
reducing
substance
use

Cochrane
libraries,
PUBMED,
CINAHL
(through
September
2013)

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

4

Opiate addicted
pregnant women
(OUD not
specified);
inpatient and
outpatient
settings; Austria,
USA, one
multicounty trial
(Austria,
Canada, USA)

Types of
Studies
Included

Methadone vs.
RCTs
buprenorphine or
slow-release
morphine; models
of care not
described

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane
(Higgins,
2011)

G-8

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE;
metaanalysis
done

Total
Findings
Numbers
of
Patients

271

Limited evidence of no
significant differences
between methadone and
buprenorphine or slowrelease morphine for all
outcomes

Adverse
Events

Limitations

One study
showed no
difference in
side effects
for the
mother
using
methadone
vs.
buprenorphi
ne and
significantly
less side
effects for
the infant on
buprenorphi
ne; one
study
showed no
difference in
side effects
for the
mother
using
methadone
vs. slowrelease
morphine
with one
child in each
group
experiencing
a serious
side effect
(apnea)

Focus on
effectiveness of
medications; 3
studies in
outpatient
setting (no
further details);
2 studies done
in USA

Author,
Year

Purpose of
Review

Databases
Searched,
Date of Last
Search

Number Population and Intervention
of
Setting
Characteristics
Included Characteristics
Studies

Types of
Studies
Included

Nielsen,
201629

To assess the
effects of
maintenance
agonist
pharmacother
apy for the
treatment of
pharmaceutic
al opioid
dependence

Cochrane
Drugs and
Alcohol
Group’s
Specialised
Register of
Trials,
Cochrane
Central
Register of
Controlled
Trials,
PubMed,
EMBASE,
CINAHL, ISI
Web of
Science,
PsycINFO
(through
May 2015)

6

OUD due to
pharmaceutical
opioids; 5
studies
conducted in
outpatient
setting, 1 study
hospital-based
treatment vs.
brief hospital
intervention and
treatment
referral;
USA (5 studies)
and Iran (1
study)

Methadone vs.
RCTs
buprenorphine;
also,
buprenorphine
maintenance vs.
either
buprenorphine
taper (in addition
to psychological
treatment) or brief
intervention and
referral to
treatment

RahimiTo evaluate
Movaghar, the
30
2013
effectiveness
and safety of
various
pharmacological
therapies on
maintenance
of opium
dependence
(alone or in
combination
with
psychosocial
interventions)

Cochrane
libraries,
MEDLINE,
EMBASE,
CINAHL,
PsychINFO,
regional
databases
(IMEMR and
ASCI),
national
databases
(Iranmedex
and
Iranpsych);
through
February
2012

3

OUD due to
heroin;
outpatient; Iran

Different doses of RCTs
buprenorphine
compared; one
study of baclofen
vs. placebo for
maintenance post
detoxification;
models of care
not described

Methods
for Rating
Methodological
Quality of
Primary
Studies
Cochrane
(Higgens,
2011)

Methods
for
Synthesizing
Results of
Primary
Studies
GRADE;
metaanalysis
done

Cochrane
(Higgins,
2011)

Unclear for
quality; no
metaanalysis

Total
Findings
Numbers
of
Patients

607

Methadone or
buprenorphine appeared
equally effective on opioid
use and treatment
retention; Maintenance
treatment with
buprenorphine appeared
more effective than
detoxification or
psychological treatments
on opioid use and
treatment retention

870

Higher doses of
buprenorphine
significantly increased the
treatment retention rate
compared with lower
doses; No significant
difference in maintenance
retention rate between
baclofen vs. placebo post
detoxification.

Adverse
Events

Limitations

No
difference
between
methadone
and
buprenorphi
ne on
adverse
events;
Evidence
favored
buprenorphi
ne
maintenanc
e over
detoxificatio
n or
psychologic
al treatment
on adverse
events
Not reported

Use of open
label study
designs

Focused on
effectiveness of
medications;
outpatient
setting (unclear
if primary care);
no trials in USA
(appears Asiafocused)

CCTs = controlled clinical trials; GRADE = Grading of Recommendations; Assessment; Development and Evaluations; HIV = human immunodeficiency virus; LAMM = levo-alphaacetylmethadol; MAT = medication-assisted treatment; OUD = opioid use disorder; RCT = randomized controlled trial; UK = United Kingdom; USA = United States of America; vs. = versus
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